MARTIN F. PERA
Curriculum Vitae

Business Address: The Jackson Laboratory
600 Main Street
Bar Harbor, ME 04609 USA

Business Phone: **207 288 1443**
Mobile Phone : **207 412 3080**
Email: martin.pera@jax.org
Website: https://www.jax.org/research-and-faculty/faculty/martin-pera
Citizenship: Australian and United States – Dual National

Qualifications

Undergraduate	College of William and Mary, Williamsburg, VA. U.S.A. **B.A.**, English Language and Literature 1972
PhD	George Washington University, Washington, D.C. U.S.A. **Ph.D.**, Pharmacology 1979 **Thesis title**: *Interaction of cis-dichlorodiammine platinum (II) with diuretic drugs in rodent model systems*
Fellowship	National Institutes of Health (U.S.) Postdoctoral Fellowship National Research Service Award; Institute of Cancer Research, London, United Kingdom 1979-1982
Research Fellowship	Imperial Cancer Research Fund London 1982 -1984
Masters (Honorary)	Oxford University, Oxford, U.K. **M.A.** 1990

Professional Background:

Academic Appointments

1979 – 1982	National Institutes of Health National Research Service Award Fellow; Institute of Cancer Research, London, United Kingdom
1982 – 1984	Research Fellow, Imperial Cancer Research Fund, London, U.K.
1984 – 1988	Cell Biologist, Institute of Cancer Research, Sutton, Surrey, U.K.
1989 – 1996	Group Leader, Cancer Research Campaign, Department of Zoology, Oxford University, Oxford, U.K.
1996 – 2000	Senior Research Fellow, Monash Institute of Reproduction and Development (MIRD)
1997 – 2001	Deputy Head, Centre for Early Human Development, MIRD
2000 – 2004	Associate Professor, MIRD
2001 – 2002	Co-Director, Centre for Early Human Development
2003 – 2003	Director, Centre for Early Human Development, MIRD
2003 – 2006	Founding Scientist and Member, Scientific Management Advisory Committee, National Stem Cell Centre
2004 – 2006	Research Professor and Deputy Director, Centre for Early Human Development, MIRD
2004 – 2006	Director, Embryonic Stem Cell Research, Australian Stem Cell Centre

2006- 2012	Founding Director, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California Professor of Cell and Neurobiology
2011 –2017	Chair, Stem Cell Sciences The University of Melbourne The Florey Institute of Neuroscience and Mental Health Walter and Eliza Hall Institute of Medical Research Program Leader, Stem Cells Australia – ARC/SRI
2017-	Professor, The Jackson Laboratory

Honours and Awards

1979	National Institutes of Health (U.S.) National Research Service Award
1997	Senior Scientist, Monash Institute of Reproduction and Development
2005	Management Board, International Society for the Study of Differentiation
2006	Member, the Hinxton Group
2006	Sir Louis Mathieson Distinguished Visiting Professor, Monash
2007	Distinguished Alumni Award, George Washington University
2009	Honorary Appointment, Conjoint Professor, School of Psychiatry, The University of New South Wales, Sydney, Australia
2010	Honorary Professorship, University of Queensland
2017	Honorary Professorship, University of Melbourne

Student Supervision and Training

Institute of Cancer Research

Research Students

Malcolm D. Mason MD (University of London)
Maria Jose Blaso Lafita PhD (University of Madrid)

Supervision of Postdoctoral Fellow

Dr. Susan Cooper

Oxford University

Supervision of Honours Projects

Ms. Elizabeth Harrington
Ms. Rebecca Lawrence

Supervision of Master of Science

Mr. Carl Watkins (University College London)

Supervision of PhD Students

Ms. Sherry Roach (1994)
Mr. David Banbury (1994)

Monash University

Supervision of Masters of Science projects

Mr. Tim Xiang January 1998-March 1999
Mr. Gary Peh, 2002 – 2003
Mr. A.L.Von Boxtel, Netherlands

Supervision of Honors projects

Ms. Emma Langton-Bunker, March 1998-November 1998
Mr. Ben Rollo, February 2000-Feb 2001
Mr. Adam Filipczyk, February 2000-Feb 2001
Mr. Hayden Waterham, Feb 2001-Feb 2002
Mr. Lincon Stamp, July 2002 – July 2003

Mr. Raymond Wong, January 2003 - November 2003
Ms. Genevieve Brown, January 2004
Ms. Vinali Dias from January 2004
Mr. Kevin Tvierak, 2004-2005

Supervision of PhD students

Dr. Ben Reubinoff, February 1998-2001
Ms Jessica Andrade, June 1998-June2004
Ms. Carmel Obrien, August 1998-August 2002
Mr. Adam Filipczyk, April 2001-April 2005
Ms. Kathy Davidson, January 2003 – December 2006
Ms. Elizabeth Stadler, from July 2002 – July 2010
Ms Anna Mossman, March 2003 – March 2007
Mr. Raymond Wong, Feb 2004-2007
Mr. Lincon Stamp, Feb 2004-2011
Mr. Gary Peh, Feb 2004-2006
Mr. Tom Chung, 2005-2008
Mr. Nick Hannan , 2005-2008
Ms. Caterina Grandela, 2004-2008
Ms. Adelia Lin, 2005-2008
Supervision of Postdoctoral Fellows
Dr. Souheir Houssami
Dr. Susan Hawes
Dr. Andrew Laslett
Dr. Alice Pebay
Dr. Mirella Dottori
Dr. Ernst Wolvetang

University of Southern California 2006

Supervision of Medical Student projects

Mr. David Braxton, 2006- 2010

Supervision of PhD. Student

Ms. Crystal Sengstaken, 2007- 2010
Mr. Jordan Pomeroy, 2007-
Ms. Juliana Jung, 2008-2011

Supervision of Postdoctoral Fellows

Dr. Victoria Fox, 2007-2008
Dr. Kouichi Hasegawa, 2007- 2009
Dr. Jun Wu, 2008-

PhD Committees (Qualifying) 2007

Eric Schulze
Rashidi Narges
Ankita Das
Eszter Pais
Steven Tsai
Zong Wei

University of Melbourne 2012 - 2016

Supervision of PhD Student

Duncan Crombie completed 2016
Stephanie Bellmaine completed 2016
Elizabeth Mason completed 2017
Marcelo Leal MD
Terri Ann Harris

Supervision of International Interns

Jorien van Rooijen (2012) University of Amsterdam
Ksenia Finogenova (2013) Ludwig-Maximilians-University Munich
Maria Helenda Dirven (2015) University of Leiden,
Danila Vittori MD (2015) University of Rome, Sant' Andrea Hospital

Ana Lauxen (2016) University of Groningen, The Netherlands

The Jackson Laboratory 2017-

Supervision of Postdoctoral Fellow
Dr. Daniel Cortes
Supervision of PhD students
Ms. Candice Byers, PhD committee
Ms. Sarah Heurer, PhD committee
Mr. Alex Stanton, PhD Tufts University student
Ms. Jiaxin Li, PhD student
Ms. Lauren Kuffler, PhD committee

Supervision of International Intern
Ms. Melanie Escudero, Ecole Normale Superiore, Lyon, France.
Supervision of Post-Baccalaureate Fellows
Mr. Kevin Hayes
Ms. Queen Imogu
Supervision of Summer Students
Ms. Nicole Wilkinson
Ms. Julia Fiore
Ms. Alyssa Edwards
Mr. Yun Kim (MITACS Scholar, University of Toronto)
Ms. Nicole da Costa
Ms. English Laserna
Ms. Nicole da Costa, English Laserna

Courses, Lectures, In-house presentations

The Jackson Laboratory

To be updated.

The University of Melbourne

FMDHS Dean's Lecture Series 2011, "Pluripotent Human Stem Cells: A Progress Report", 10 November 2011

Department of Genetics Seminar Program at La Trobe University (Melbourne), "Defining Pluripotency" 15 March 2012

Centre for Eye Research Australia, Department of Ophthalmology, UoM, "The States of Pluripotency", 2 May 12

PhD Coursework in Neuroscience – University of Melbourne, "Human Pluripotent Stem Cells As Research Tools & Emerging Applications in Medicine", 4 May 2012

Biomedical Science Depart of Anatomy and Neuroscience UoM, "Human Pluripotent Stem Cells: The Road Ahead", 16 May, 2012

Anatomy and Cell Biology, UoM, seminar series semester one, "Pluripotency and Lineage Specification in Human Embryonic Stem Cells," 18 May 2012

Murdoch Children's Research Institute Molecular Medicine Seminar, "Pluripotent Stem Cells: States and Fates," 29 May 2012

Research Mentors Program Workshop 3, "Session on challenges and opportunities for women research leaders," 29th May 2012

Melbourne Neuroscience Institute Public Seminar Series, "Stem Cells & Regenerative Medicine: The Future is Now" 26 June 2012

Biomedical Sciences , "Stem Cells – Basic Science," August 2012

Melbourne School of Land and Environment, "Biotechnology Stem Cells and Applications," October 2012

Department of Anatomy and Neuroscience, "Clinical translation of Pluripotent Stem Cell," August 2013

Biomedical Sciences, "Stem Cells – Basic Science," September 2013

Victorian Institute of Forensic Medicine, "Stem cells under the microscope," June 2016

Biomedical Sciences, "Modelling of human disease with pluripotent stem cells," August 2014

Biomedical Sciences, "Clinical translation of pluripotent stem cell therapy," August 2014

Biomedical Sciences, "Stem cells in Development and Regeneration."

Biomedical Sciences, "Modelling of human disease with pluripotent stem cells," August 2015

Biomedical Sciences, "Clinical translation of pluripotent stem cell therapy," August, 2015

Melbourne Neuroscience Institute PhD workshop, September 2015

University of Southern California

Lectures for CIRM Stem Cell Biology course 2006-2010
"Concepts of Pluripotency"
"Embryonic Stem Cells"
"Tissue Stem Cells, Pluripotency and Cloning"

Lecture for Medical School – Hematology
"Embryonic Stem Cells" 2007-2010
Pharmacology Laboratory, Medical School 2008-2010

Monash University, Melbourne, Australia

Lecture to Masters of Reproductive Science program, Monash University 1997-1998

Lecturing, Practicals ANAT 3052, 2003

Supervision of Minor Projects in Physiology, Monash University 1998

Deputy Director and Course Module Coordinator, Masters of Clinical Embryology, Monash University, Development of this Course Module MCE 101

Introduction to Mammalian Development 2000-2004, Director of Course, 2003

Lecturing in MCE101, Introduction to Mammalian Development, 2000 -2004

Additional Teaching Responsibilities

Instructor, University of Pittsburgh Frontiers in Human Embryonic Stem Cells 2003 and 2004

Jackson Laboratories, "Current Protocols in Human Embryonic Stem Cells", 2002, 2003.

Director 2004-2009.

Executive Administrative Roles

Monash University, 1998 - 2003

Director, Centre for Early Human Development, 2003

Co-Director, Centre for Early Human Development, 2001-2002

Chair of Senior Scientist Forum, Monash Institute of Reproduction and Development, 2001

Student Advisor, Centre for Early Human Development, 1998-1999

University of Southern California, 2006-2012

Direct a major new initiative in stem cell biology, the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, at the Keck School of Medicine.
Develop scientific strategy for the basic research program of the Center, conduct recruitment of staff, participate in fundraising for the new initiative, develop liaisons with other groups at USC, regional and international centers, mentor young faculty, work with Dean's Office and administrators to manage the new institute, participate in planning and development of new research facilities, develop and implement strategies for commercialization and technology transfer of Center research, represent the University in public on matters relating to stem cell research, and maintain leading work in human embryonic stem cells.

In 2006, I left Monash University and the Australian Stem Cell Centre to take up the post of Foundation Director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California. Stem cell research was a new initiative for the USC. During my tenure the Center grew to comprise twelve faculty members and over 100 staff and students and a small administrative support team. I was responsible for development of the new program and recruitment of the faculty. The Center faculty comprises mostly young scientists from leading laboratories around the world. I played a very important part in mentoring these young scientists in their first independent appointments. While I was Director, our Faculty have published their research findings in major journals including Cell, Nature, Proceedings of the National Academy of Sciences, Nature Biotechnology, Cell Stem Cell, Developmental Cell, Cancer Research, and others. Center Faculty won $38.7 million in competitive research funding, exclusive of our CIRM building grant, from the NIH and CIRM, plus a number of foundations. Three Center members, Dr. Qilong Ying, Dr. Mani Pashmfaroush, and Dr. Gage Crump, won prestigious CIRM New Faculty Awards. At the time of my departure USC/CHLA ranked fourth in CIRM funding across the State, in a very competitive environment that encompasses some of the leading universities in America and the world (UCLA, UCSF, UCSD, Stanford, UCBerkeley, and others). I authored the Major Facilities Grant, which was essential to help put up The Center's new building, supported by a generous gift of $30 million from the Broad Foundation and a competitive grant award of $27 million from CIRM (a CIRM Institute Grant). We opened the building in October 2010. The five story, 80000 square foot structure houses a vivarium, a lecture theatre, and three floors of laboratories for Center investigators. Another research floor houses four state of the art core laboratories (stem cell, flow cytometry, imaging and chemical genomics) which I set up, and serves as a hub for training and collaborative research with PIs from other USC departments and local institutions.

The USC Broad research pipeline included a number of technologies that will find application in the clinical delivery of stem cell therapies. These include a new stem cell modulatory drug targeted at the Wnt pathway, now in Phase 1 clinical trial for colorectal cancer and leukemia (developed by Professor Michael Kahn), novel animal models for the study of human disease and drug development based on rat embryonic stem cells (developed by Assistant Professor Qilong Ying), development of embryonic stem cell therapies for macular degeneration, a novel marker for liver stem cells and cancer of the pancreas and esophagus that emerged from studies in my own laboratory. I was a Co-investigator on a successful USC CIRM Disease Team application funded at $16 million to develop an embryonic stem cell based treatment for macular degeneration.

Member, Dean's Executive Council and Dean's Research Advisory Group

2011-2016: University of Melbourne

I returned to Melbourne to lead a successful bid for the ARC Special Research Initiative in Stem Cell Sciences, Stem Cells Australia. Simultaneously I took up the Chair of Stem Cell Sciences at the University of Melbourne, The Walter and Eliza Hall Institute and the Florey Neuroscience and Mental Health Institute. SCA is a 7 year, $21 million dollar initiative that brings together an interdisciplinary team of Australia's leading researchers in the field to address key fundamental questions in stem cell biology. The program has has met all major KPIs for each year of its existence. We completed a successful interim review in 2014 and received renewal of funding to 2018. Our scientists have published groundbreaking findings in Nature Cell Biology, Cell, Cell Stem Cell, Nature Biotechnology, and a range of other leading journals. SCA has become the leading scientific force in stem cell research and regenerative medicine in Australia. We have also lead a very important national

campaign against a loophole in the Australian regulations on cell therapy that is allowing clinics to provide unproven stem cell treatments outside of a clinical trial context. This campaign culminated in a major change in the Therapeutic Goods Administration policy on autologous stem cell therapy, which strengthened regulation of stem cell clinics throughout Australia.
Within the University of Melbourne node of SCA, I established a new stem cell research unit, complete with two core laboratories that support researchers throughout the Parkville precinct and holds a regular seminar program, and provides seed funding for new initiatives. We are working with our neuroscience colleagues in the University and the Florey Neuroscience and Mental Health Institute to develop human pluripotent stem cell platforms for neuroscience research.

Committee Membership

Monash University

1996-2003	Annual Report Committee, MIRD
1996-2003	Cloning Symposium Committee, MIRD
1996-2003	Building Committee, MIRD
1996-2003	Postgraduate Student Committee, MIRD
1996-2003	Chair, Equipment Committee, MIRD
1996-2003	Chair, Senior Scientists Forum, MIRD
2002-2003	Research Degrees Committee, Monash University

University of Southern California

2008-	Search Committee for Chair of Pediatrics, CHLA
2008-	Search Committee, Division Chief, Bone Marrow Transplantation and Research Immunology, CHLA,
2008-	Dean's Executive Council
2008-	Dean's Research Council
2008-	Strategic Plan Central Committee
	KSOM Clinical Research Retreat
	SCRO Committee Member
	Dean's Teaching Retreat
	Biomedical Nanoscience Retreats
	Search Committee, CIRM Leadership Award

The University of Melbourne

2011-	Melbourne Neuroscience Institute Advisory Board
2011-	Centre for Neural Engineering Advisory Board
2013-2014	Research Review, Precision Medicine

The Jackson Laboratory

2017-	Tufts JAX Track Admission Committee
2017-2018	Convenor, REDIG Stem Cells and Regenerative Biology
2018-	Seminar Committee
2018-2020	Faculty Recruiting Committee
2018-2020	Scientific Advisory Committee
2018-	Scientific Services Faculty Partner, Cell Engineering
2022-	Faculty Partner, Cell Engineering
2022-	JAX Center for Precision Medicine
2022-	JAX Center for Vision Research
2022-	JAX Cancer Center
2022-	University of Maine, NSFA Dean Search, Postdoctoral Training, Bar Harbor
2022-	Thesis Committee for Candice Byers, Sarah Heurer, and Lauren Kuffler

Society Memberships

Past

British Society for Cell Biology

British Society for Developmental Biology
Australia/New Zealand Society for Cell and Developmental Biology
International Society of Differentiation (Board of Directors from 2004-2010)
Australasian Society for Stem Cell Research (2011-2016)

Current
International Society for Stem Cell Research

Professional Activities

Local/ National/ International

1999-	Provide public commentary on scientific and ethical aspects of research on human embryonic stem cells and therapeutic cloning. Member, Victorian Government Working Party on Stem Cell Research
2002-2004	Member, Scientific Management Advisory Council of the National Stem Cell Centre Provided advice to national, state, and foreign government and regulatory agencies on therapeutic cloning and embryonic stem cells
2004-2006	Member, Executive Scientific Operating Committee, Australian Stem Cell Centre
2004-	Member, International Stem Cell Forum Steering Group
2004-2010	Member, Board of Management, International Society for the Study of Differentiation
2004-2006	Member, Gene and Related Therapies Research Advisory Panel, NHMRC
2005-2010	Scientific Advisory Board, National Stem Cell Bank
2005-2006	Ad Hoc Member, NIH Study Sections Neurogenesis and Cell Fate
2006-2010	Member, International Society for Stem Cell Research Standards Committee
2006-2009	Reviewer, Juvenile Diabetes Research Foundation
2007-	Connecticut Stem Cell Research Peer Review Committee
2008-2010	Scientific Advisory Board of the Canadian Stem Cell Network
2008-2010	Prize Committee, The Meira and Shaul Massry Foundation, Massry Award
2008-	Committee Chair, Canada Foundation for Innovation Leading Edge/New Initiatives in Stem Cells
2009-2010	Member, Scientific Advisory Board Charter of the Australian Stem Cell Centre
2009-2011	Board of Trustees Committee on Science and Engineering Complex, George Washington University
2009-2010	Scientific Advisory Board, ES Tools (EU Embryonic Stem Cell Consortium)
2009	CIRM UK MRC meeting January
2009-2015	Chair, ISSCR Membership Committee
2009 -2012	Member, ISSCR Audit Committee
2015 -	Clerk, and Member, Board of Directors, ISSCR
2015-	Strategic Oversight Committee, ISSCR
2016 -2018	Embryo Research Licensing Committee—NHMRC
2017-	Chair, International Stem Cell Initiative Genetic and Epigenetics Study Group
2018	Chair, Education Task Force, ISSCR

Grant reviews

NHMRC, ARC, US NIH, UK BBSRC, UK MRC, Wellcome Trust, Yorkshire Cancer Research Campaign, Israel Science Foundation, European Community, other international bodies, Connecticut Stem Cell Research, Tri Institutional, JDRF Research Program (New York), Canada Foundation for Innovation, California Institute of Regenerative Medicine, New Zealand HRC Biomedical, Singapore National Research Foundation, Networks of Centres of Excellence of Canada, NREC Canada

Editorial Boards

2000-2003	Reproduction Fertility and Development
2004-	Stem Cells
2007-	Stem Cell Research
2008-	Cell Stem Cell

2009-2017	PLoS One
2012-	Stem Cell Reports
2016-	Elife
2019-	Editor in Chief, Stem Cell Reports

Journal Reviews

*** (Regular ad-hoc reviewer)**

PNAS
International Journal of Cancer
Experimental Cell Research
Science
Reproduction Fertility and Development (Editorial Board 2000-2003)
*Nature
*Nature Medicine
*Stem Cells (Editorial Board from 2004)
*Nature Biotechnology
*Nature Methods
Molecular Reproduction and Development
*Nature Genetics
*Nature Cell Biology
Developmental Biology
Journal of Anatomy
The Journal of Cell Science
Current Biology
Mechanisms of Development
*Development
Journal of Pathology
Human Reproduction
Journal of Anatomy
International Journal of Developmental Biology
*Cell Stem Cell (Editorial Board from 2008)
Human Reproductive Differentiation
Molecular Biology of the Cell
*Stem Cell Research (Editorial Board 2007)
*Stem Cell Reports
*Cell
*Cell Reports
*Nature Commentary

Consultantships, affiliations with Biotechnology companies

1996 – 2000	Consultant, Stem Cell Sciences Pty. Ltd.
1996 -	Director, Biotrophix Pty. Ltd.
2000 - 2002	Founding Scientist and member of the Scientific Advisory Board, ESI Pte. Ltd.
2002-2005	Founding Scientist, Copy Rat Pty. Ltd.
2003-2006	Founding Scientist and Driver, Nephrogenix
2006-2010-	Consultant, Australian Stem Cell Centre
2007-2010	Consultant, Millipore Corporation
2012 -2013	Consultant UCB Pharmaceuticals

Research Activities

Major Areas of Research Interest

Human embryonic stem cells and human development; extrinsic control of growth and differentiation of human pluripotent stem cells; human germ cell tumors of the testis

Research Summary Past Ten Years

2006-2011 **Professor of Cell & Neurobiology**
Founding Director Eli & Edythe Broad Centre Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California Prospective isolation and characterization of cellular subpopulations in human ES cell cultures-the primordial stem cell and lineage specification; role of NF-κB signaling in epigenetic and genetic adaptation of human ES cells in vitro; derivation of liver stem cells from human ES cell cultures; novel cell surface markers for endodermal progenitors; the International Stem Cell Initiative; Comparison of ES cells with iPS cells.

2011 – 2017 **Chair of Stem Cell Sciences**
The University of Melbourne, Australia
Florey Neuroscience and Mental Health Institute, Australia
Walter and Eliza Hall Institute of Medical Research Australia
Program Leader, Stem Cells Australia – ARC/Special Research Initiative
Extrinsic Regulation of Pluripotency and Self Renewal in Human Pluripotent Stem Cells
Human Pluripotent Stem Cells in Antibody Discovery
Human Pluripotent Stem Cell Platforms for Neuroscience
Regulation of Stem Cell Therapy Clinics in Australia

2017-present **The Jackson Laboratory**
Extrinsic control of growth and differentiation of human pluripotent stem cells
Human pluripotent stem cell and mouse models of neurodevelopmental gene disorders and repair in the adult central nervous system
Functional analysis of candidate susceptibility alleles for macular degeneration

Other Research Achievements

1974 - 1979 **Ph.D. Student, Department of Pharmacology, George Washington University, Washington, D.C.**
Studied the pharmacology and toxicology of the antitumour agent cisplatin; demonstrated protection from renal toxicity and an improved therapeutic index when the drug was used in combination with diuretics in rodent model systems.

1979-1982 **N.I.H. National Research Service Award, Institute of Cancer Research, London, U.K.**
Carried out molecular pharmacological studies of cisplatin, which provided strong evidence for the role of DNA binding and repair in the response of normal and tumour cells to the drug.

1982-1984 **Postdoctoral Fellow, Imperial Cancer Research Fund, London, U.K.**
Developed a new culture system for normal mouse keratinocytes and keratinocytes from preneoplastic and malignant stages of skin carcinogenesis in the mouse. Proved that immortality and reduced growth factor dependence preceded malignant transformation in skin tumour development. Showed that resistance to the induction of terminal differentiation by tumour promoting phorbol esters was a characteristic of premalignant keratinocytes derived from papillomas.

1984-1989 **Cell Biologist, Institute of Cancer Research, Sutton, U.K**.
Established and characterized a panel of cell lines from human germ cell tumours, which constitute a unique resource for the study of growth and differentiation in early human embryogenesis and in testicular tumours. Produced new monoclonal antibodies for the analysis of cell differentiation lineage in these neoplasms. Obtained evidence for the critical role of the serum adhesion protein vitronectin in the growth of human germ cell tumours. Demonstrated that germ cell tumours were inherently sensitive to DNA damage induced by cisplatin. Collaborated on the development and characterization of a panel of human lung carcinoma cell lines.

1989-1996 **Group Leader, Department of Zoology, Oxford University, Oxford, U.K.**
Played a major role in international collaborative studies on the phenotypes and cell lineages of human germ cell tumours, and on the basis of their sensitivity to cytotoxic drugs. Discovered a new keratan sulphate proteoglycan expressed in human embryonal carcinoma, other tumours, and foetal tissues; reported on the purification, biochemical characterization, and tissue distribution of this new

pericellular matrix molecule; showed its potential use as a serum tumour marker. Carried out cell and molecular studies of gene expression during retinoic acid-induced differentiation of multipotent human embryonal carcinoma stem cells into endoderm. Characterised a novel polypeptide factor, which promotes growth and inhibits differentiation of multipotent embryonal carcinoma stem cells. Identified CD30 and CD30 ligand as potential autocrine regulators of human embryonal carcinoma stem cells. Collaborated with several groups to examine the expression of activin and related molecules in human germ cell tumours, work which led to the identification of human GDF-3 as a stem cell marker and possible growth regulator.

1996-2006 **Senior Research Fellow Associate Professor, and Research Professor Monash Institute of Reproduction and Development, Monash University, Clayton, Victoria**
Developed novel assay for human multipotent stem cell factor, which will allow expression cloning of this molecule. Completed studies on induction of differentiation of human pluripotent stem cells by BMP-2. Completed collaborative study on novel forms of Leukemia Inhibitory Factor produced by human germ cell tumours. Completed collaborative study on cytogenetic changes in cell lines from human germ cell tumours. Carried out further studies elucidating role of CD30 and its ligand in human germ cell tumours, which demonstrated production of truncated form of the receptor in these cells and established a role of CD30 in stem cell survival. Directed and participated in project which resulted in establishment and characterization of human embryonic stem cell lines from blastocysts and the derivation of pure cultures of neuronal progenitors there from. Carried out research on spontaneous differentiation of human embryonic stem cells identifying BMP-2 as a molecular mediator and noggin as an inducer of stem cell differentiation.

Research Funding
Since 1996

Grants obtained at Monash University

Chief Investigator, "In vitro model for investigating the effects of genetic abnormalities on early human development." Rebecca L. Cooper Medical Research Foundation. $10,695

"*Increasing IVF success rates by optimisation of culture conditions to produce viable blastocysts for transfer and cryopreservation*." Monash IVF. $2,500

1997 Chief Investigator, Stem Cell Sciences Pty. Ltd. Research Agreement. $75,000.

1998 Chief Investigator, Stem Cell Sciences Pty. Ltd. Research Agreement. $75,000.

1998 Wellcome Foundation Equipment Grant. $200,000.

1998 Chief Investigator, "*Cell biology of human peri-implantation development*." Monash IVF. $20,000.

1998 Chief Investigator, ARC, APAI award. $20,502.

1999 Chief Investigator, NHMRC Project Grant. "*Combinatorial Regulation of Human Multipotent Stem Cells by Membrane Bound and Soluble Factors*." $110,000.

Monash University Special Research Fund. Centre for Animal Clonal Genomics for Biomedicine. $160,000.

1999 Chief Investigator, "*Human embryonic stem cells in biology and medicine*," Monash University Special Research Fund. $160,000.

2000-2001 Chief Investigator, "*Growth and Differentiation of human embryonic stem cells*." ESI. $525,000

2001-2003 Chief Investigator, "*Growth and Differentiation of human embryonic stem cells*." ESI. $900,000: per annum.

2001-2006 "*Creating Islet cells to cure Type I diabetes*," NHMRC/JDRF Program Grant. $852,000 per annum.

2002-2005 Chief Investigator, "*Control of growth and differentiation of normal and malignant pluripotent human stem cells*," NHMRC Project Grant. $160,000 per annum.

2001 Chief Investigator, Monash University SMURF 2, "*Development of square wave technologies for human embryonic stem cells and other cell types*," Equipment grant, $30,000.

Chief Investigator, National Institutes of Health Stem Cell Infrastructure Grant, with ES Cell International.

2002-2005 Chief Investigator, National Institute of Health (NIH) Research Grant, "*Towards Renal Regeneration*," US $99,000.

2003 – 2006 Chief Investigator, National Institute of Health (NIH) Research Grant, "*Regulation of Embryonic Stem Cells*," US $232,674.

2002-2006 Chief Investigator, Biotechnology Centre of Excellence Award, ARC & Biotechnology of Australia-Commonwealth Government. A $43.5M.

2004-2006 Chief Investigator, Biotechnology Centre of Excellence Award, ARC & Biotechnology of Australia-Commonwealth Government. $500K per annum

2004-2006 Biotechnology Innovation Fund: Nephrogenix Pty Ltd, Project Number: BIF03275, "*Developing Cell based therapies for kidney disease*."

2005-2006 Juvenile Diabetes Research Foundation, "*Characterization of novel embryonic stem cell lines*," US $125,248.

Grants obtained at the University of Southern California

2008-2011 Principal Investigator, CIRM USC Center for Stem Cell and Regenerative Medicine, Shared Research Laboratory and Course in Current Protocols in Human Embryonic Stem Cell Research, $3,523,244

2007-2009 Principal Investigator, NIH USC, Center for Liver Disease Pilot Grant, US $63,309/2 years.

2007 -2009 Principal Investigator, CIRM Seed Grant : RS1-00222-1, "*Therapeutic Potential of Retinal Pigment Epithelial Cell Derived from HES cells for Retinal Degeneration*," $653,661.

2007-2008 CIRM Major Facilities Grant, $26.9 million, authored grant on behalf of the Provost of the University of Southern California.

2008-2011 Principal Investigator, CIRM New Cell Lines Award RL1-00667-1, "*New technology for the derivation of human pluripotent stem cell lines for clinical use*," $1,387,508.

2008-2010 Principal Investigator, Whittier Foundation Award, "*Cancer Stem Cells Leading the Way*," $72,800.00.

2009-2014 Associate Investigator, NIH/NIDDK 5U01DK084538-02 (Wang) Establishment of CHLA's Children Clinical Center, $1,413,458 (9/10/2009-5/31/14).

2009-2013 Co-Principal Investigator, CIRM Disease Team Award, "*Stem cell based treatment strategy for age-related macular degeneration (AMD*)," $15,914,317.

2009-2012 Principal Investigator, CIRM Basic Biology Award RB1-01372, "*The stem cell microenvironment in the maintenance of pluripotency and reprogramming*," $1,440,822.

Grants obtained at The University of Melbourne

2011-2018 ARC, "Special Research Initiative in Stem Cell Science," $21,000,000.

2012-2015 Human Science Frontiers Program RGP0001/2012, "*Stem Cell Dynamics in Time and Space*," CI US $900,000.

2012-2014 Australia-India Strategic Research Fund BF060012, "*Novel Cell Surface Markers for Endodermal Progenitor Cells in Health and Disease*," CI $297,000.

2014-2016 NHMRC 2014 Project Grant 1059369, "*Uncovering the pathogenesis of age-related macular degeneration using induced pluripotent stem cells*," CIC $552,000.

2016-2018 NHMRC 2015 Project Grant 1106027, "*Modelling epileptic encephalopathies using induced stem cells*," CIB $506,489.

Grants obtained at the Jackson Laboratory

2021-2024 Principal Investigator, BR-CMM-0321-0804-JAXLAB-FFA-02, "*Precision Functional Genomics for Modeling Pathogenesis of Age Related Macular Degeneration*," Foundation Fighting Blindness (3/1/2021-2/29/2024)

2020-2025 Demonstration Project Lead, 1U54OD030187-02, "*DMU Core: AMD Project*," NIH/ORIP (9/1/2020-8/31/2025)

2019-2021 Principal Investigator, THOME-2019-MP, "*Functional genomics analysis of the impact of disruption of extracellular matrix genes in early stages of AMD*," The Edward N. & Della L. Thome Memorial Foundation (2/1/2019-1/31/2021)

2019-2021 Principal Investigator, DIF-FY19-Humanized Mice, "*New Routes to Humanized Mice via Pluripotent Stem Cells V2.0*," The Jackson Laboratory (3/4/2019-12/31/2021)

Issued US Patents

Reubinoff, B.E., **Pera, M.F.**, Fong, C-Y. Trounson, A.O., Bongso, A. "Embryonic stem cells." U.S. Patent No. 6,875,607. ES Cell International PTE Ltd.,Singapore, SG (2005).

Reubinoff, B.E., **Pera, M.F.**, Ben-Hur, T.. 2006. "Implanting neural progenitor cells derived for human embryonic stem cells." U.S. Patent No. 7,011,828. ES Cell International PTE Ltd., Singapore, SG, (2006).

Pera, M.F. 2006. "Methods of culturing embryonic stem cells and controlled differentiation." U.S. Patent No. 7,112,437. ES Cell International PTE Ltd., Singapore, SG (2006).

Pebay, A.M., **Pera, M.F.**. 2008. "Methods of regulating differentiation in stem cells." 2008. U.S. Patent No. 7,413,903. ES Cell International PTE Ltd., Victoria, AU, (2008).

Pebay, A.M., **Pera, M.F.** 2009. "Methods of regulating differentiation in stem cells." U.S. Patent No. 7,604,990, Singapore, SG (2009).

Reubinoff, B.E., **Pera, M.F.**, Ben-Hur, T. "Embryonic stem cells and neural progrenitor cells derived therefrom." U.S. Patent No. 7,504,257. ES Cell International PTE Ltd., Singapore, SG (2009).

Reubinoff, B.E., **Pera, M.F.**, Ben-Hur, T. "Embryonic stem cells and neural progenitor cells derived therefrom." U.S. Patent No. 7,947,498. ES Cell International PTE Ltd., Singapore, SG (2011).

Pera, M.F., Hawes, S., Stamp, L., Crosby, H., Strain, A. "Cell marker for hepatic and pancreatic stem cells and progenitor cells." U.S. Patent No. 8,119,774 (2012).

Pera, M.F., Zinberg, T.L., Hasegawa K. 2012. "Induction, progagation and isolation of liver progenitor cells." U.S. Patent No. 8,278,105. University of Southern California, Los Angeles, CA (2012).

Pera, M.F., Zinberg, T., Hasegawa, K. "Induction, propagation and isolation of liver progenitor cells." U.S. Patent 20120329152 (2012).

Reubinoff, B.E., **Pera, M.F.**, Ben-Hur, T. "Neural progenitor cells derived from embryonic stem cells." U.S. Patent 8,137,969. ES Cell International PTE Ltd., Singapore, SG (2012).

Reubinoff, B.E., **Pera, M.F.**, Ben-Hur, T. "Neural progenitor cells derived from embryonic stem cells." U.S. Patent No. 8,460,931. ES Cell International PTE Ltd., Singapore, SG (2013).

Pera, M.F. "Culturing human embryonic stem cells with a noggin to generate cells lacking Pax-6 expression." U.S. Patent No. 9,080,147. ES Cell International PTE Ltd., Singapore, SG (2015).

Dissertation:

Pera, M.F. Interaction of cis-dichlorodiammine platinum (II) with diuretic drugs in rodent model systems. Ph.D. dissertation, Graduate School of Arts and Sciences, The George Washington University, Washington, D.C (1979)

Peer Reviewed Publications (Citations below in March 2019, Google Scholar. In June 2021, Total cites 222935, since 2016, 5902; h index 65, since 2016, 42).

1. **Pera, M.F.**, Jr. & Harder, H.C. Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245-1249 (1977). [Citations: 117]
2. **Pera, M.F.**, Jr. & Harder, H.C. Effects of mannitol or furosemide diuresis on cis-dichlorodiammineplatinum(II) antitumor activity and toxicity to host-renewing cell populations in rats. Cancer Res 39: 1279-1286 (1979). [Citations: 22]
3. **Pera, M.F.**, Jr., Zook, B.C. & Harder, H.C. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res 39: 1269-1278 (1979). [Citations: 136]
4. **Pera, M.F.**, Jr., Rawlings, C.J. & Roberts, J.J. The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem Biol Interact 37: 245-261 (1981). [Citations: 83]
5. **Pera, M.F.**, Jr., Rawlings, C.J., Shackleton, J. & Roberts, J.J. Quantitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinum(II) (cisplatin). II. Comparison of results from alkaline elution, DNA renaturation and DNA sedimentation studies. Biochim Biophys Acta 655: 152-166 (1981). [Citations: 101]
6. **Pera, M.F.**, Jr., Sessford, D. & Roberts, J.J. Toxicity of cisplatin and hydroxymalonatodiammine platinum (II) towards mouse bone marrow and B16 melanoma in relation to DNA binding in vivo. Biochem Pharmacol 31: 2273-2278 (1982). [Citations: 12]
7. Parkinson, E.K., **Pera, M.F.**, Emmerson, A. & Gorman, P.A. Differential effects of complete and second-stage tumour promoters in normal but not transformed human and mouse keratinocytes. Carcinogenesis 5: 1071-1077 (1984). [Citations: 40]
8. **Pera, M.F.** & Gorman, P.A. *In vitro* analysis of multistage epidermal carcinogenesis: development of indefinite renewal capacity and reduced growth factor requirements in colony forming keratinocytes precedes malignant transformation. Carcinogenesis 5: 671-682 (1984). [Citations: 34]
9. Duchesne, G.M., Eady, J.J., Peacock, J.H. & **Pera, M.F.** A panel of human lung carcinoma lines: establishment, properties and common characteristics. Br J Cancer 56: 287-293 (1987). [Citations: 38]
10. **Pera, M.F.**, Blasco Lafita, M.J. & Mills, J. Cultured stem-cells from human testicular teratomas: the nature of human embryonal carcinoma, and its comparison with two types of yolk-sac carcinoma. Int J Cancer 40: 334-343 (1987). [Citations: 94]
11. **Pera, M.F.**, Friedlos, F., Mills, J. & Roberts, J.J. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res 47: 6810-6813 (1987). [Citations: 56]
12. Cooper, S. & **Pera, M.F.** Vitronectin production by human yolk sac carcinoma cells resembling parietal endoderm. Development 104: 565-574 (1988). [Citations: 27]
13. Duchesne, G., Cassoni, A. & Pera, M. Radiosensitivity related to neuroendocrine and endodermal differentiation in lung carcinoma lines. Radiother Oncol 13: 153-161 (1988). [Citations: 16]
14. **Pera, MF,** Blasco-Lafita, MJ, Cooper, S, Mason, M, Mills, J & Monaghan, P. Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells. Differentiation 39: 139-149 (1988). [Citations: 94]
15. **Pera, M.F.**, Cooper, S., Mills, J. & Parrington, J.M. Isolation and characterization of a multipotent clone of human embryonal carcinoma cells. Differentiation 42: 10-23 (1989). [Citations: 176]
16. **Pera, M.F.**, Roach, S. & Elliss, C.J. Comparative biology of mouse and human embryonal carcinoma. Cancer Surv 9: 243-262 (1990). [Citations: 20]
17. Mason, M.D. & **Pera, M.F.** Biochemical analysis and cellular location of the GCTM-2 antigen in embryonal carcinoma and in other tumour cell lines. Recent Results Cancer Res 123: 59-61 (1991). [Citations: 1]
18. Mason, M.D., **Pera, M.F.** & Cooper, S. Possible presence of an embryonal carcinoma-associated proteoglycan in the serum of patients with testicular germ cell tumours. Eur J Cancer 27: 300 (1991). [Citations: 8]

19. **Pera, M.F.**, Cooper, S., Bennet, W. & Crawford-Bryce, I. Human embryonal carcinoma and yolk sac carcinoma in vitro: cell lineage relationships and possible paracrine growth regulatory interactions. Recent Results Cancer Res 123: 51-58 (1991). [Citations: 2]

20. Rinke de Wit, T.F., Wilson, L., van den Elsen, P.J., Thielen, F., Brekhoff, D., Oosterhuis, J.W., **Pera, M.F.** & Stern, P.L. Monoclonal antibodies to human embryonal carcinoma cells: antigenic relationships of germ cell tumors. Lab Invest 65: 180-191 (1991). [Citations: 5]

21. Cooper, S., **Pera, M.F.**, Bennett, W. & Finch, J.T. A novel keratan sulphate proteoglycan from a human embryonal carcinoma cell line. Biochem J 286 (Pt 3): 959-966 (1992). [Citations: 53]

22. Mason, M.D. & **Pera, M.F.** Immunohistochemical and biochemical characterisation of the expression of a human embryonal carcinoma cell proteoglycan antigen in human germ cell tumours and other tissues. Eur J Cancer 28A: 1090-1098 (1992). [Citations: 7]

23. Roach, S., Cooper, S., Bennett, W. & **Pera, M.F.** Cultured cell lines from human teratomas: windows into tumour growth and differentiation and early human development. Eur Urol 23: 82-87; discussion 87-88 (1993). [Citations: 46]

24. Hill, B.T., Scanlon, K.J., Hansson, J., Harstrick, A., **Pera, M**., Fichtinger-Schepman, A.M. & Shellard, S.A. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 30A: 832-837 (1994). [Citations: 69]

25. Roach, S., Schmid, W. & **Pera, M.F.** Hepatocytic transcription factor expression in human embryonal carcinoma and yolk sac carcinoma cell lines: expression of HNF-3 alpha in models of early endodermal cell differentiation. Exp Cell Res 215: 189-198 (1994). [Citations: 32]

26. Wenk, J., Andrews, P.W., Casper, J., Hata, J., **Pera, M.F.**, von Keitz, A., Damjanov, I. & Fenderson, B.A. Glycolipids of germ cell tumors: extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int J Cancer 58: 108-115 (1994). [Citations: 82]

27. **Pera, M.F.**, Koberle, B. & Masters, J.R. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer 71: 904-906 (1995). [Citations: 27]

28. Andrews, P.W., Casper, J., Damjanov, I., Duggan-Keen, M., Giwercman, A., Hata, J., von Keitz, A., Looijenga, L.H., Millan, J.L., Oosterhuis, J.W., **Pera, M.**, Sawada, M., Schmoll, H.J., Skakkebaek, N.E., van Putten, W. & Stern, P. Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Int J Cancer 66: 806-816 (1996). [Citations: 149]

29. **Pera, M.F.**, Bennett, W. & Cerretti, D.P. Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors. Lab Invest 76: 497-504 (1997). [Citations: 39]

30. Caricasole, A.A., van Schaik, R.H., Zeinstra, L.M., Wierikx, C.D., van Gurp, R.J., van den Pol, M., Looijenga, L.H., Oosterhuis, J.W., **Pera, M.F.**, Ward, A., de Bruijn, D., Kramer, P., de Jong, F.H. & van den Eijnden-van Raaij, A.J. Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. Oncogene 16, 95-103 (1998). [Citations: 117]

31. Henegariu, O., Vance, G.H., Heiber, D., **Pera, M**. & Heerema, N.A. Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes. J Mol Med (Berl) 76: 648-655 (1998). [Citations: 41]

32. **Pera, M.F.**, Bennett, W. & Cerretti, D.P. CD30 and its ligand: possible role in regulation of teratoma stem cells. APMIS 106: 169-172; discussion 173 (1998). [Citations: 24]

33. **Pera, M.F.** & Herszfeld, D. Differentiation of human pluripotent teratocarcinoma stem cells induced by bone morphogenetic protein-2. Reprod Fertil Dev 10: 551-555 (1998). [Citations: 48]

34. Trounson, A. & **Pera, M**. Potential benefits of cell cloning for human medicine. Reprod Fertil Dev 10: 121-125 (1998). [Citations: 40]

35. Voyle, R.B., Haines, B.P., **Pera, M.F.**, Forrest, R. & Rathjen, P.D. Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins. Exp Cell Res 249: 199-211 (1999). [Citations: 35]

36. Hooper, J.D., Bowen, N., Marshall, H., Cullen, L.M., Sood, R., Daniels, R., Stuttgen, M.A., Normyle, J.F., Higgs, D.R., Kastner, D.L., Ogbourne, S.M., **Pera, M.F.**, Jazwinska, E.C. & Antalis, T.M. Localization, expression and genomic structure of the gene encoding the human serine protease testisin. Biochim Biophys Acta 1492: 63-71 (2000). [Citations: 53]

37. Munsie, M.J., Michalska, A.E., O'Brien, C.M., Trounson, A.O., **Pera, M.F.** & Mountford, P.S. Isolation of pluripotent embryonic stem cells from reprogrammed adult mouse somatic cell nuclei. Curr Biol 10: 989-992 (2000). [Citations: 457]

38. **Pera, M.F.**, Reubinoff, B. & Trounson, A. Human embryonic stem cells. J Cell Sci 113 (Pt 1): 5-10 (2000). [Citations: 759]

39. Reubinoff, B.E., **Pera, M.F.**, Fong, C.Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 18: 399-404 (2000). [Citations: 3719]

40. Douglas, M.L., Boucaut, K.J., Antalis, T.M., Higgins, C., **Pera, M.F.**, Stuttgen, M.A. & Nicol, D.L. An orthotopic xenograft model of human nonseminomatous germ cell tumour. Br J Cancer 85: 608-611 (2001). [Citations: 7]

41. Hayes, E., Galea, S., Verkuylen, A., Pera, M., Morrison, J., Lacham-Kaplan, O. & Trounson, A. Nuclear transfer of adult and genetically modified fetal cells of the rat. Physiol Genomics 5: 193-204 (2001). [Citations: 63]

42. **Pera, M.F.** Scientific considerations relating to the ethics of the use of human embryonic stem cells in research and medicine. Reprod Fertil Dev 13: 23-29 (2001). [Citations: 30]

43. **Pera, M.F.** Human pluripotent stem cells: a progress report. Curr Opin Genet Dev 11: 595-599 (2001). [Citations: 59]

44. Reubinoff, B.E., Itsykson, P., Turetsky, T., **Pera, M.F.**, Reinhartz, E., Itzik, A. & Ben-Hur, T. Neural progenitors from human embryonic stem cells. Nat Biotechnol 19: 1134-1140 (2001). [Citations: 1462]

45. Reubinoff, B.E., **Pera, M.F.**, Vajta, G. & Trounson, A.O. Effective cryopreservation of human embryonic stem cells by the open pulled straw vitrification method. Hum Reprod 16: 2187-2194 (2001). [Citations: 397]

46. Trounson, A. & **Pera, M**. Human embryonic stem cells. Fertil Steril 76: 660-661 (2001).

47. Cooper S, Bennett W, Andrade J, Reubinoff BE, Thomson J, **Pera MF**. Biochemical properties of a keratan sulphate/chondroitin sulphate proteoglycan expressed in primate pluripotent stem cells. *J Anat* 200: 259-65. (2002). [Citations: 37]

48. Goto, T., Jones, G.M., Lolatgis, N., **Pera, M.F.**, Trounson, A.O. & Monk, M. Identification and characterisation of known and novel transcripts expressed during the final stages of human oocyte maturation. Mol Reprod Dev 62: 13-28 (2002). [Citations: 50]

49. Healy, D.L., Weston, G., **Pera, M.F.**, Rombauts, L. & Trounson, A.O. Human cloning 2001. Hum Fertil (Camb) 5: 75-77 (2002). [Citations: 4]

50. Mummery, C., Ward, D., van den Brink, C.E., Bird, S.D., Doevendans, P.A., Opthof, T., Brutel de la Riviere, A., Tertoolen, L., van der Heyden, M. & **Pera, M**. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 200: 233-242 (2002). [Citations: 416]

51. Sathananthan H, **Pera M**, Trounson A. The fine structure of human embryonic stem cells. *Reprod Biomed Online* 4: 56-61. (2002). [Citations: 149]

52. Laslett, A.L., Filipczyk, A.A. & **Pera, M.F.** Characterization and culture of human embryonic stem cells. Trends Cardiovasc Med 13: 295-301 (2003). [Citations: 79]

53. Mummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., van der Heyden, M., Opthof, T., **Pera, M**., de la Riviere, A.B., Passier, R. & Tertoolen, L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107: 2733-2740 (2003). [Citations: 1453]

54. Ben-Hur, T., Idelson, M., Khaner, H., **Pera, M**., Reinhartz, E., Itzik, A. & Reubinoff, B.E. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22: 1246-1255 (2004). [Citations: 456]

55. Henegariu, O., Heerema, N.A., Thurston, V., Jung, S.H., **Pera, M**. & Vance, G.H. Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet Cytogenet 148: 14-20 (2004). [Citations: 17]

56. **Pera, M.F.**, Andrade, J., Houssami, S., Reubinoff, B., Trounson, A., Stanley, E. G., Ward-van Oostwaard, D. & Mummery, C. Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin. J Cell Sci 117: 1269-1280 (2004). [Citations: 579]

57. Wong, R.C., Pebay, A., Nguyen, L.T., Koh, K. L. & **Pera, M.F**. Presence of functional gap junctions in human embryonic stem cells. Stem Cells 22: 883-889 (2004).

58. Itsykson, P., Ilouz, N., Turetsky, T., Goldstein, R. S., Pera, M. F., Fishbein, I., Segal, M. & Reubinoff, B. E. Derivation of neural precursors from human embryonic stem cells in the presence of noggin. Mol Cell Neurosci 30: 24-36 (2005). [Citations: 266]

59. Stamp, L., Crosby, H.A., Hawes, S.M., Strain, A.J. & **Pera, M.F.** A novel cell-surface marker found on human embryonic hepatoblasts and a subpopulation of hepatic biliary epithelial cells. Stem Cells 23: 103-112 (2005). [Citations: 28]

60. Herszfeld, D., Wolvetang, E., Langton-Bunker, E., Chung, T.L., Filipczyk, A.A., Houssami, S., Jamshidi, P., Koh, K., Laslett, A.L., Michalska, A., Nguyen, L., Reubinoff, B.E., Tellis, I., Auerbach, J.M., Ording, C.J., Looijenga, L.H. & **Pera, M.F.** CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotechnol 24: 351-357 (2006). [Citations: 181]

61. Taylor, R.A., Cowin, P.A., Cunha, G.R., **Pera, M**., Trounson, A.O., Pedersen, J. & Risbridger, G.P. Formation of human prostate tissue from embryonic stem cells. Nat Methods 3: 179-181 (2006). [Citations: 114]

62. Wong, R.C., Dottori, M., Koh, K.L., Nguyen, L.T., **Pera, M.F.** & Pebay, A. Gap junctions modulate apoptosis and colony growth of human embryonic stem cells maintained in a serum-free system. Biochem Biophys Res Commun 344: 181-188 (2006). [Citations: 67]

63. Costa, M., Dottori, M., Sourris, K., Jamshidi, P., Hatzistavrou, T., Davis, R., Azzola, L., Jackson, S., Lim, S. M., **Pera, M.**, Elefanty, A. G. & Stanley, E. G.. A method for genetic modification of human embryonic stem cells using electroporation. Nat Protoc 2: 792-796 (2007). [Citations: 186]

64. Dai, W., Field, L. J., Rubart, M., Reuter, S., Hale, S. L., Zweigerdt, R., Graichen, R. E., Kay, G. L., Jyrala, A. J., Colman, A., Davidson, B. P., **Pera, M.** & Kloner, R. A. Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J Mol Cell Cardiol 43: 504-516 (2007). [Citations: 192]

65. Davidson, K. C., Jamshidi, P., Daly, R., Hearn, M. T., **Pera, M. F.** & Dottori, M. Wnt3a regulates survival, expansion, and maintenance of neural progenitors derived from human embryonic stem cells. Mol Cell Neurosci 36: 408-415 (2007). [Citations: 83]

66. Filipczyk, A.A., Laslett, A.L., Mummery, C. & **Pera, M.F.** Differentiation is coupled to changes in the cell cycle regulatory apparatus of human embryonic stem cells. Stem Cell Res 1: 45-60 (2007). [Citations: 117]

67. Grandela, C., **Pera, M.F.**, Grimmond, S.M., Kolle, G. & Wolvetang, E.J. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res 1: 116-128 (2007). [Citations: 92]

68. Heck, A. J., Mummery, C., Whetton, A., Oh, S., Lee, B., **Pera, M.**, Lemischka, I. & Krijgsveld, J. Proteome biology of stem cells. Stem Cell Res 1: 7-8 (2007). [Citations: 11]

69. Ilancheran, S., Michalska, A., Peh, G., Wallace, E. M., **Pera, M.** & Manuelpillai, U. Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 77: 577-588 (2007). Stem cells derived from human fetal membranes display multilineage differentiation potential. Biol Reprod 77: 577-588 (2007). [Citations: 549]

70. International Stem Cell, I. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 25: 803-816 (2007). [Citations: 1234]

71. Orkin, S.H. & **Pera, M.** Stem cells down under-ISSCR 2007. Cell Stem Cell 1: 271-276 (2007). [Citations: 5]

72. Wolvetang, E.J., **Pera, M.F.** & Zuckerman, K.S. Gap junction mediated transport of shRNA between human embryonic stem cells. Biochem Biophys Res Commun 363: 610-615 (2007). [Citations: 71]

73. Wong, R.C., Tellis, I., Jamshidi, P., **Pera, M.** & Pebay, A. Anti-apoptotic effect of sphingosine-1-phosphate and platelet-derived growth factor in human embryonic stem cells. Stem Cells Dev 16: 989-1001 (2007). [Citations: 64]

74. Bera, T. K., Saint Fleur, A., Ha, D., Yamada, M., Lee, Y., Lee, B., Hahn, Y., Kaufman, D. S., **Pera, M.** & Pastan, I. Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells. Stem Cells Dev 17: 325-332 (2008).

75. Li, P., Tong, C., Mehrian-Shai, R., Jia, L., Wu, N., Yan, Y., Maxson, R. E., Schulze, E. N., Song, H., Hsieh, C. L., **Pera, M. F.** & Ying, Q. L. Germline competent embryonic stem cells derived from rat blastocysts. Cell 135: 1299-1310 (2008). [Citations: 761]

76. Wong, R.C., **Pera, M.F.** & Pebay, A. Role of gap junctions in embryonic and somatic stem cells. Stem Cell Rev 4: 283-292 (2008). [Citations: 94]

77. Enver, T., **Pera, M.**, Peterson, C. & Andrews, P.W. Stem cell states, fates, and the rules of attraction. Cell Stem Cell 4: 387-397 (2009). [Citations: 359]

78. Hannan, N.R., Jamshidi, P., **Pera, M.F.** & Wolvetang, E.J. BMP-11 and myostatin support undifferentiated growth of human embryonic stem cells in feeder-free cultures. Cloning Stem Cells 11: 427-435 (2009). [Citations: 39]

79. Hough, S.R., Laslett, A.L., Grimmond, S.B., Kolle, G. & **Pera, M.F.** A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells. PLoS One 4: e7708 (2009). [Citations: 178]

80. Peh, G.S., Lang, R.J., **Pera, M.F.** & Hawes, S.M. CD133 expression by neural progenitors derived from human embryonic stem cells and its use for their prospective isolation. Stem Cells Dev 18: 269-282 (2009). [Citations: 73]

81. Tanaka, M., Jokubaitis, V., Wood, C., Wang, Y., Brouard, N., **Pera, M.**, Hearn, M., Simmons, P. & Nakayama, N. BMP inhibition stimulates WNT-dependent generation of chondrogenic mesoderm from embryonic stem cells. Stem Cell Res 3: 126-141 (2009).

82. Wei, Z., Yang, Y., Zhang, P., Andrianakos, R., Hasegawa, K., Lyu, J., Chen, X., Bai, G., Liu, C., **Pera, M.** & Lu, W. Klf4 interacts directly with Oct4 and Sox2 to promote reprogramming. Stem Cells 27: 2969-2978 (2009).

83. Wong, R.C., Davidson, K.C., Leung, J., **Pera, M.F.** & Pebay, A. Acute effect of endothelins on intercellular communication of human embryonic stem cells. J Stem Cells 4: 47-56 (2009). [Citations: 3]

84. Chung, T. L., Brena, R. M., Kolle, G., Grimmond, S. M., Berman, B. P., Laird, P. W., **Pera, M. F.** & Wolvetang, E. J. Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells 28: 1848-1855 (2010). [Citations: 166]

85. Chung, T. L., Turner, J. P., Thaker, N. Y., Kolle, G., Cooper-White, J. J., Grimmond, S. M., **Pera, M. F.** & Wolvetang, E. J. Ascorbate promotes epigenetic activation of CD30 in human embryonic stem cells. Stem Cells 28: 1782-1793 (2010). [Citations: 54]

86. Hasegawa, K., Pomeroy, J.E. & **Pera, M.F.** Current technology for the derivation of pluripotent stem cell lines from human embryos. Cell Stem Cell 6: 521-531 (2010). [Citations: 36]

87. Hasegawa, K., Zhang, P., Wei, Z., Pomeroy, J. E., Lu, W. & **Pera, M. F.** Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion. Stem Cells 28: 1338-1348 (2010). [Citations: 39]

88. International Stem Cell Initiative, C., Akopian, V., Andrews, P. W., Beil, S., Benvenisty, N., Brehm, J., Christie, M., Ford, A., Fox, V., Gokhale, P. J., Healy, L., Holm, F., Hovatta, O., Knowles, B. B., Ludwig, T. E., McKay, R. D., Miyazaki, T., Nakatsuji, N., Oh, S. K., **Pera, M. F.**, Rossant, J., Stacey, G. N. & Suemori, H. Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells. In Vitro Cell Dev Biol Anim 46: 247-258 (2010). [Citations: 222]

89. Lin, S. A., Kolle, G., Grimmond, S. M., Zhou, Q., Doust, E., Little, M. H., Aronow, B., Ricardo, S. D., **Pera, M. F.**, Bertram, J. F. & Laslett, A. L. Subfractionation of differentiating human embryonic stem cell populations allows the isolation of a mesodermal population enriched for intermediate mesoderm and putative renal progenitors. Stem Cells Dev 19: 1637-1648 (2010). [Citations: 46]

90. **Pera, M.F.** & Tam, P.P. Extrinsic regulation of pluripotent stem cells. Nature 465: 713-720 (2010). [Citations: 357]

91. Vazey, E. M., Dottori, M., Jamshidi, P., Tomas, D., **Pera, M. F.**, Horne, M. & Connor, B. Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease. Cell Transplant 19: 1055-1062 (2010). [Citations: 35]

92. International Stem Cell, I. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 29: 1132-1144 (2011). [Citations: 359]

93. Zhu, D., Deng, X., Spee, C., Sonoda, S., Hsieh, C. L., Barron, E., **Pera, M.** & Hinton, D. R. Polarized secretion of PEDF from human embryonic stem cell-derived RPE promotes retinal progenitor cell survival. Invest Ophthalmol Vis Sci 52: 1573-1585 (2011).

94. Polarized secretion of PEDF from human embryonic stem cell-derived RPE promotes retinal progenitor cell survival. Invest Ophthalmol Vis Sci 52: 1573-1585 (2011).

95. Cunningham, J.J., Ulbright, T.M., **Pera, M. F.** & Looijenga, L.H. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 30: 849-857 (2012). [Citations: 175]

96. Hasegawa, K., Yasuda, S. Y., Teo, J. L., Nguyen, C., McMillan, M., Hsieh, C. L., Suemori, H., Nakatsuji, N., Yamamoto, M., Miyabayashi, T., Lutzko, C., **Pera, M. F.** & Kahn, M. Wnt signaling orchestration with a small molecule DYRK inhibitor provides long-term xeno-free human pluripotent cell expansion. Stem Cells Transl Med 1: 18-28 (2012). [Citations: 60]

97. Kearns-Jonker, M., Dai, W., Gunthart, M., Fuentes, T., Yeh, H. Y., Gerczuk, P., **Pera, M.**, Mummery, C. & Kloner, R. A. Genetically Engineered Mesenchymal Stem Cells Influence Gene Expression in Donor Cardiomyocytes and the Recipient Heart. J Stem Cell Res Ther S1 (2012).

98. Lee, N. S., Rohan, J. G., Zitting, M., Kamath, S., Weitz, A., Sipos, A., Salvaterra, P. M., Hasegawa, K., **Pera, M.** & Chow, R. H. A novel dual-color reporter for identifying insulin-producing beta-cells and classifying heterogeneity of insulinoma cell lines. PLoS One 7: e35521 (2012).

99. Stamp, L. A., Braxton, D. R., Wu, J., Akopian, V., Hasegawa, K., Chandrasoma, P. T., Hawes, S. M., McLean, C., Petrovic, L. M., Wang, K. & Pera, M. F. The GCTM-5 epitope associated with the mucin-like glycoprotein FCGBP marks progenitor cells in tissues of endodermal origin. Stem Cells 30: 1999-2009 (2012). [Citations: 23]

100. Wong, R.C., **Pera, M.F.** & Pebay, A. Maintenance of human embryonic stem cells by sphingosine-1-phosphate and platelet-derived growth factor. Methods Mol Biol 874: 167-175 (2012). Citations: 10]

101. Avery, S., Hirst, A. J., Baker, D., Lim, C. Y., Alagaratnam, S., Skotheim, R. I., Lothe, R. A., **Pera, M. F.**, Colman, A., Robson, P., Andrews, P. W. & Knowles, B. B. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Reports 1: 379-386 (2013). [Citations: 125]

102. Kim, H., Wu, J., Ye, S., Tai, C. I., Zhou, X., Yan, H., Li, P., **Pera, M**. & Ying, Q. L. Modulation of beta-catenin function maintains mouse epiblast stem cell and human embryonic stem cell self-renewal. Nat Commun 4: 2403 (2013).

103. Bird, M. J., Needham, K., Frazier, A. E., van Rooijen, J., Leung, J., Hough, S., Denham, M., Thornton, M. E., Parish, C. L., Nayagam, B. A., **Pera, M**., Thorburn, D. R., Thompson, L. H. & Dottori, M. Functional characterization of Friedreich ataxia iPS-derived neuronal progenitors and their integration in the adult brain. PLoS One 9: e101718 (2014).

104. Davidson, K.C., Guymer, R.H., **Pera, M.F.** & Pebay, A. Human pluripotent stem cell strategies for age-related macular degeneration. Optom Vis Sci 91: 887-893 (2014). [Citations: 11]

105. Hough, S. R., Thornton, M., Mason, E., Mar, J. C., Wells, C. A. & **Pera, M. F.** Single-cell gene expression profiles define self-renewing, pluripotent, and lineage primed states of human pluripotent stem cells. Stem Cell Reports 2: 881-895 (2014). [Citations: 76]

106. Mason, E. A., Mar, J. C., Laslett, A. L., **Pera, M. F.**, Quackenbush, J., Wolvetang, E. & Wells, C. A. Gene expression variability as a unifying element of the pluripotency network. Stem Cell Reports 3: 365-377 (2014). [Citations: 19]

107. Munsie, M. & **Pera, M.** Regulatory loophole enables unproven autologous cell therapies to thrive in Australia. Stem Cells Dev 23 Suppl 1: 34-38 (2014).

108. Andrews, P. W., Baker, D., Benvinisty, N., Miranda, B., Bruce, K., Brustle, O., Choi, M., Choi, Y. M., Crook, J. M., de Sousa, P. A., Dvorak, P., Freund, C., Firpo, M., Furue, M. K., Gokhale, P., Ha, H. Y., Han, E., Haupt, S., Healy, L., Hei, D. J., Hovatta, O., Hunt, C., Hwang, S. M., Inamdar, M. S., Isasi, R. M., Jaconi, M., Jekerle, V., Kamthorn, P., Kibbey, M. C., Knezevic, I., Knowles, B. B., Koo, S. K., Laabi, Y., Leopoldo, L., Liu, P., Lomax, G. P., Loring, J. F., Ludwig, T. E., Montgomery, K., Mummery, C., Nagy, A., Nakamura, Y., Nakatsuji, N., Oh, S., Oh, S. K., Otonkoski, T., **Pera, M.**, Peschanski, M., Pranke, P., Rajala, K. M., Rao, M., Ruttachuk, R., Reubinoff, B., Ricco, L., Rooke, H., Sipp, D., Stacey, G. N., Suemori, H., Takahashi, T. A., Takada, K., Talib, S., Tannenbaum, S., Yuan, B. Z., Zeng, F. & Zhou, Q. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med 10: 1-44 (2015).

109. Crombie, D. E., Van Bergen, N., Davidson, K. C., Anjomani Virmouni, S., McKelvie, P. A., Chrysostomou, V., Conquest, A., Corben, L. A., Pook, M. A., Kulkarni, T., Trounce, I. A., **Pera, M. F.**, Delatycki, M. B. & Pebay,

A. Characterization of the retinal pigment epithelium in Friedreich ataxia. Biochem Biophys Rep 4: 141-147 (2015). [Citations: 6]

110. Davidson, K.C., Mason, E.A. & **Pera, M.F.** The pluripotent state in mouse and human. Development 142: 3090-3099 (2015). [Citations: 142]

111. Denham, M., Hasegawa, K., Menheniott, T., Rollo, B., Zhang, D., Hough, S., Alshawaf, A., Febbraro, F., Ighaniyan, S., Leung, J., Elliott, D. A., Newgreen, D. F., **Pera, M. F.** & Dottori, M. Multipotent caudal neural progenitors derived from human pluripotent stem cells that give rise to lineages of the central and peripheral nervous system. Stem Cells 33: 1759-1770 (2015). [Citations: 83]

112. **Pera, M. F.**, de Wert, G., Dondorp, W., Lovell-Badge, R., Mummery, C. L., Munsie, M. & Tam, P. P. What if stem cells turn into embryos in a dish? Nat Methods 12: 917-919 (2015). [Citations: 63]

113. Crombie, D.E., **Pera, M.F.**, Delatycki, M.B. & Pebay, A. Using human pluripotent stem cells to study Friedreich ataxia cardiomyopathy. Int J Cardiol 212: 37-43 (2016). [Citations: 5]

114. Pomeroy, J. E., Hough, S. R., Davidson, K. C., Quaas, A. M., Rees, J. A. & **Pera, M. F.** Stem Cell Surface Marker Expression Defines Late Stages of Reprogramming to Pluripotency in Human Fibroblasts. Stem Cells Transl Med 5: 870-882 (2016). [Citations: 6]

115. Bellmaine, S. F., Ovchinnikov, D. A., Manallack, D. T., Cuddy, C. E., Elefanty, A. G., Stanley, E. G., Wolvetang, E. J., Williams, S. J. & **Pera, M.** Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells. Elife 6 (2017). [Citations: 18]

116. Crombie, D. E., Curl, C. L., Raaijmakers, A. J., Sivakumaran, P., Kulkarni, T., Wong, R. C., Minami, I., Evans-Galea, M. V., Lim, S. Y., Delbridge, L., Corben, L. A., Dottori, M., Nakatsuji, N., Trounce, I. A., Hewitt, A. W., Delatycki, M. B., **Pera, M. F.** & Pebay, A. Friedreich's ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. Aging (Albany NY) 9: 1440-1452 (2017). [Citations: 25]

117. Ding, S., Kingshott, P., Thissen, H., **Pera, M.** & Wang, P.Y. Modulation of human mesenchymal and pluripotent stem cell behavior using biophysical and biochemical cues: A review. Biotechnol Bioeng 114: 260-280 (2017).

118. **Pera, M.F.** Human embryo research and the 14-day rule. Development 144: 1923-1925 (2017). [Citations: 42]

119. Abbot, S., Agbanyo, F., Ahlfors, J. E., Baghbaderani, B. A., Bartido, S., Bharti, K., Burke, C., Carlsson, B., Cavagnaro, J., Creasey, A., DiGiusto, D., Francissen, K., Gaffney, A., Goldring, C., Gorba, T., Griffiths, E., Hanatani, T., Hayakawa, T., Heki, T., Hoogendoorn, K., Kawamata, S., Kimura, H., Kirkeby, A., Knezevic, I., Lebkowski, J., Lin, S., Lin-Gibson, S., Lubiniecki, A., O'Shea, O., **Pera, M.**, Petricciani, J., Pigeau, G., Ratcliffe, A., Sato, Y., Schumann, G. G., Shingleton, W., Stacey Chair, G., Sullivan, S., Svendsen, C. N., Trouvin, J. H., Vandeputte, J., Yuan, B. Z. & Zoon, K. Report of the international conference on manufacturing and testing of pluripotent stem cells. Biologicals 56: 67-83 (2018).

120. Allison, T. F., Andrews, P. W., Avior, Y., Barbaric, I., Benvenisty, N., Bock, C., Brehm, J., Brüstle, O., Damjanov, I., Elefanty, A., Felkner, D., Gokhale, P. J., Halbritter, F., Healy, L. E., Hu, T. X., Knowles, B. B., Loring, J. F., Ludwig, T. E., Mayberry, R., Micallef, S., Mohamed, J. S., Müller, F.-J., Mummery, C. L., Nakatsuji, N., Ng, E. S., Oh, S. K. W., O'Shea, O., **Pera, M. F**., Reubinoff, B., Robson, P., Rossant, J., Schuldt, B. M., Solter, D., Sourris, K., Stacey, G., Stanley, E. G., Suemori, H., Takahashi, K., Yamanaka, S. & The International Stem Cell, I. Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells. Nature Communications 9: 1925 (2018). [Citations: 51]

121. Baker, C.L. & **Pera, M.F.** Capturing Totipotent Stem Cells. Cell Stem Cell 22: 25-34 (2018). [Citations: 64]

122. Gazina, E. V., Morrisroe, E., Mendis, G. D. C., Michalska, A. E., Chen, J., Nefzger, C. M., Rollo, B. N., Reid, C. A., **Pera, M. F.** & Petrou, S. Method of derivation and differentiation of mouse embryonic stem cells generating synchronous neuronal networks. J Neurosci Methods 293: 53-58 (2018). [Citations: 12]

123. Farley, A. M., Braxton, D. R., Li, J., Trounson, K., Sakar-Dey, S., Nayer, B., Ikeda, T., Lau, K. X., Hardikar, W., Hasegawa, K. & **Pera, M. F.** Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma. Sci Rep 9: 2876 (2019). [Citations: 3]

124. Harkness, L., Chen, X., Jia, Z., Davies, A. M., Monteiro, M., Gray, P. & **Pera, M.** Fibronectin-conjugated thermoresponsive nanobridges generate three dimensional human pluripotent stem cell cultures for differentiation towards the neural lineages. Stem Cell Res 38: 101441 (2019).

125. Eaves, C.J. & **Pera, M.F.** Cancer Stem Cells: Notes for Authors. Stem Cell Reports 14: 167-168 (2020).

126. Hyun, I., Munsie, M., **Pera, M.F.**, Rivron, N.C. & Rossant, J. Toward Guidelines for Research on Human Embryo Models Formed from Stem Cells. Stem Cell Reports 14: 169-174 (2020). [Citations: 37]
127. Lau, K. X., Mason, E. A., Kie, J., De Souza, D. P., Kloehn, J., Tull, D., McConville, M. J., Keniry, A., Beck, T., Blewitt, M. E., Ritchie, M. E., Naik, S. H., Zalcenstein, D., Korn, O., Su, S., Romero, I. G., Spruce, C., Baker, C. L., McGarr, T. C., Wells, C. A. & **Pera, M. F.** Unique properties of a subset of human pluripotent stem cells with high capacity for self-renewal. Nat Commun 11: 2420 (2020). [Citations: 14]
128. **Pera, M**. Diversity, Equity, and Inclusion in Stem Cell Research. Stem Cell Reports 15: 803 (2020).
129. **Pera, M**. Message from the Editor: Stem Cell Science in the Time of COVID-19. Stem Cell Reports 14: 529 (2020).
130. Cortes, D. & **Pera, M.F.** The genetic basis of inter-individual variation in recovery from traumatic brain injury. NPJ Regen Med 6: 5 (2021). [Citations: 9]
131. Hayes, K., Kim, Y.K. & **Pera, M.F.** A case for revisiting Nodal signaling in human pluripotent stem cells. Stem Cells 39: 1137-1144 (2021). [Citations: 1]
132. Moris, N., Alev, C., **Pera, M**. & Martinez Arias, A. Biomedical and societal impacts of in vitro embryo models of mammalian development. Stem Cell Reports 16: 1021-1030 (2021).
133. Mummery, C., Little, M., Lin, H., Clark, A., Zaret, K., ISSCR Board 2020-2021, Srivastava, D., Fuchs, E., Watt, F. & Temple, S. Mentorship in Science: Response to AlShebli et al., Nature Communications 2020. Stem Cell Reports 16: 1-2 (2021).
134. **Pera, M**. Updates for contributors: Rigor and reproducibility in stem cell research. Stem Cell Reports 16: 1645 (2021).
135. **Pera, M.F.** & Rossant, J. The exploration of pluripotency space: Charting cell state transitions in peri-implantation development. Cell Stem Cell 28: 1896-1906 (2021). [Citations: 2]
136. Chakraborty, A. R., Vassilev, A., Jaiswal, S. K., O'Connell, C. E., Ahrens, J. F., Mallon, B. S., **Pera, M. F.** & DePamphilis, M. L. Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors. Stem Cell Reports 17: 397-412 (2022). [Citations: 1]
137. Collin, G. B., Shi, L., Yu, M., Akturk, N., Charette, J. R., Hyde, L. F., Weatherly, S. M., **Pera, M. F.**, Naggert, J. K., Peachey, N. S., Nishina, P. M. & Krebs, M. P. A Splicing Mutation in Slc4a5 Results in Retinal Detachment and Retinal Pigment Epithelium Dysfunction. Int J Mol Sci 23 (2022). [Citations:]
138. Cortes, D. E., Escudero, M., Mitra, A., Korgan, A. C., Edwards, A., O'Connell, K. M. S., Reinholdt, L. G. & **Pera, M. F**. An *in vitro* neurogenetics platform for precision disease modeling in the mouse. bioRxiv: 2022.2001.2021.477242 (2022).
139. Rossant, J. and **Pera, M**. The exploration of pluripotency space. In preparation.
140. McGarr, T. et al. Reference cell lines reference cell lines for the analysis of oncogeic transformation of human pluripotent stem cells. In preparation.

Chapters and Invited Commentaries

1. Roberts, J.J., and **Pera, M.F**. Action of platinum antitumour drugs in Molecular aspects of anticancer drug action. Cancer Research, Volume 48, S. Neidle and M.J. Waring, eds. MacMillan Press, London, pp. 183-231. (1983). Citations [18]
2. Roberts, J.J., and **Pera, M.F.** DNA As A Target For Anticancer Coordination Compounds. In: Platinum, gold, and other metal chemotherapeutic agents. S.J. Lippard, Editor. American Chemical Society, Washington, DC. Chapter 1, pp. 3-23. (1983). [Citations: 48]
3. Roberts, J.J., Knox, R.J., **Pera, M.F.**, Friedlos, F. and Lydall, D. The role of platinum-DNA interactions in the cellular toxicity and antitumour effects of platinum coordination compounds. In: Platinum and other metal coordination compounds in cancer chemotherapy. M. Nicolini, ed. Martin Ninhoff, The Netherlands, pp. 16-31. (1988). (Citations: 27)
4. **Pera, M.F**. Testicular germ cell tumours. In: Human Cancer in Primary Culture, A Handbook, Developments in Oncology. J. Masters, ed. Kluwer Academic Publishers, Dordrecht, The Netherlands. pp. 169-185. (1991) [Citations: 4]

5. Cooper, S., Bennett, W., Roach, S., and **Pera, M.F.** Vitronectin expression in human germ cell tumours and normal mouse development. In: Biology of vitronectins and their receptors. K.T.Preissner, S.Rosenblatt, C . Kost, and J.Wegerhoff, eds. Elsevier Medica, London, pp. 83-91. (1993)
6. **Pera, M.F.** Differentiation and Cancer. In: Oxford Textbook of Oncology. M. Peckham, H. Pinedo, and U. Veronesi, eds. Oxford University Press, Oxford. (1995). [Citations: 1]
7. **Pera MF**. Testicular germ cell tumors. In: Human Cell Culture Vol. II, Cancer Cell Lines Part 2. Kluwer Academic Publishers, Netherland, p. 127 – 149 (1999).
8. **Pera, M.F.** Biology of human testicular germ cell tumours. Reproductive Medicine Review 7(2): 141-154 (1999). [Citations: 2]
9. Trounson, AO, **Pera, M.F.** and Samananthan, AH. Fertilisation, Early Development and Implantation. In Turnbulls Obstetrics and Gynecology. G. Chamberlain and P. Steer,. Eds. Churchill Livingstone, London (2001)
10. Verfaillie C.M., **Pera, M.F.**, Landsford, P.M. Stem Cells: Hype and Reality. Hematology Am Soc Hematol Educ Program 369-391 (2002). [Citations: 412]
11. **Pera, M**. Overview of the Current Status of Research on Human Pluripotent Stem Cells. *Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz* **45,** 123–129 (2002). [Citations: 3]
12. **Pera, M.F.** Filipcyk, A. Hawes, S. Laslett, A. Isolation, Characterization, and Differentiation of Human Embryonic Stem Cells. In "Methods in Enzymology" . Wassarman P. and Keller G., eds. Vol 365 Section IV. 429-446 (2003) [Citations 64]
13. **Pera, M.F.** Unnatural selection of cultured human embryonic stem cells? Nature Biotechnology 22: 42-43, 2004. [Citations 47]
14. **Pera, M.F.** Stem cell culture, one step at a time. Nat Methods. 2: 164-165 (March 2005). [Citations: 7]
15. **Pera, M. F.** On the road to reprogramming. Stem Cell Res 1: 103-104 (2007). [Citations 9]
16. Whetton, A. D., Williamson, A. J., Krijgsveld, J., Lee, B. H., Lemischka, I., Oh, S., **Pera, M**., Mummery, C. & Heck, A. J. The time is right: proteome biology of stem cells. Cell Stem Cell 2: 215-217 (2008). [Citations 17]
17. Dottori, M. & **Pera, M.F.** Neural differentiation of human embryonic stem cells. Methods Mol Biol 438: 19-30 (2008). Citations 1]
18. **Pera, M.F.** Stem cells. A new year and a new era. Nature 451: 135-136 (2008). [Citations: 48]
19. **Pera, M.F.** & Hasegawa, K. Simpler and safer cell reprogramming. Nat Biotechnol 26: 59-60 (2008). [Citations: 48]
20. Krijgsveld, J., Whetton, A.D., Lee, B., Lemischka, I., Oh, S., **Pera, M.**, Mummery, C. & Heck, A.J. Proteome biology of stem cells: a new joint HUPO and ISSCR initiative. Mol Cell Proteomics 7: 204-205 (2008). [Citations 12]
21. **Pera, M**. Celebrating 10 years of hESC lines: an interview with Martin Pera. Stem Cells 27: 278-279 (2009).
22. **Pera, M.F.** Stem cells: Low-risk reprogramming. Nature 458: 715-716 (2009). [Citations 15]
23. Andrews, P.W., Benvenisty, N., Knowles, B.B., McKay, R.D., Oh, S.K., **Pera, M.F.**, Rossant, J. & Stacey, G.N. Human ES cell lines--introduction. In Vitro Cell Dev Biol Anim 46: 167-168 (2010). [Citations 3]
24. **Pera, M.F.** Defining pluripotency. Nat Methods 7: 885-887 (2010). [Citations: 10]
25. **Pera, M.F.** Safely modulating the immune system in regenerative medicine. Cell Stem Cell 8: 246-247 (2011). [Citations 1]
26. **Pera, M.F.** Stem cells: The dark side of induced pluripotency. Nature 471: 46-47 (2011). [Citations 320]
27. **Pera, M.F.** The proteomes of native and induced pluripotent stem cells. Nat Methods 8: 807-808. (2011). [Citations: 3]
28. **Pera, M.F.** & Plath, K. Cell reprogramming. Curr Opin Genet Dev 22: 401-402 (2012). [Citations: 1]
29. Wong, R.C., **Pera, M.F.** & Pebay, A. Maintenance of human embryonic stem cells by sphingosine-1-phosphate and platelet-derived growth factor. Methods Mol Biol 874: 167-175 (2012).
30. **Pera, M.F.,** Trouson A., Cloning debate: Stem-cell researchers must stay engaged. Nature 498 (7453): 159-161 (2013) [Citations 1]

31. Tam P.P., **Pera, M.F**. Stem Cell science and regenerative medicine. Bioessays 35(3): 147-148 2013. [Citations 1]
32. **Pera, M.F.** Epigenetics, vitamin supplements and cellular reprogramming. Nat Genet 45: 1412-1413 (2013). [Citations: 8]
33. **Pera, M.F.** Stress management: a new path to pluripotency. Cell Stem Cell 14: 273-274 (2014).
34. **Pera, M. F.** In search of naivety. Cell Stem Cell 15 (5): 543-545 (2014). [Citations: 20]
35. Cuddy, C. E. and **Pera, M.F.** Stem Cells from the Early Embryo. In: Stem Cells, Tissue Engineering, and Regenerative Medicine. David Warburton, ed. World Scientific pp 1-23 (2015).
36. Bosley, K.S., Botchan, M., Bredenoord, A.L., Carroll, D., Charo, R.A., Charpentier, E., Cohen, R., Corn, J., Doudna, J., Feng, G., Greely, H.T., Isasi, R., Ji, W., Kim, J.S., Knoppers, B., Lanphier, E., Li, J., Lovell-Badge, R., Martin, G.S., Moreno, J., Naldini, L., **Pera, M**., Perry, A.C., Venter, J.C., Zhang, F. & Zhou, Q. CRISPR germline engineering--the community speaks. Nat Biotechnol 33: 478-486 (2015). Citations [102].
37. **Pera, M**. Biomedical engineering: In vitro amniogenesis. Nat Mater 16: 394-395 (2017).
38. **Pera, M**. Embryogenesis in a dish. Science 356: 137-138 (2017).
39. Andrews, P.W., Ben-David, U., Benvenisty, N., Coffey, P., Eggan, K., Knowles, B.B., Nagy, A., **Pera, M**., Reubinoff, B., Rugg-Gunn, P.J. & Stacey, G.N. Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. Stem Cell Reports 9: 1-4 (2017). [Citations 17]
40. Kim, J.H., Kurtz, A., Yuan, B.Z., Zeng, F., Lomax, G., Loring, J.F., Crook, J., Ju, J.H., Clarke, L., Inamdar, M.S., **Pera, M**., Firpo, M.T., Sheldon, M., Rahman, N., O'Shea, O., Pranke, P., Zhou, Q., Isasi, R., Rungsiwiwut, R., Kawamata, S., Oh, S., Ludwig, T., Masui, T., Novak, T. J., Takahashi, T., Fujibuchi, W., Koo, S.K. & Stacey, G.N. Report of the International Stem Cell Banking Initiative Workshop Activity: Current Hurdles and Progress in Seed-Stock Banking of Human Pluripotent Stem Cells. Stem Cells Transl Med 6: 1956-1962 (2017).
41. Hurlbut, J.B., Hyun, I., Levine, A.D., Lovell-Badge, R., Lunshof, J.E., Matthews, K.R.W., Mills, P., Murdoch, A., **Pera, M.F.**, Scott, C.T., Tizzard, J., Warnock, M., Zernicka-Goetz, M., Zhou, Q. & Zoloth, L. Revisiting the Warnock rule. Nat Biotechnol 35: 1029-1042 (2017). [Citations: 26]
42. Hurlbut, J.B., Hyun, I., Levine, A.D., Lovell-Badge, R., Lunshof, J. E., Matthews, K.R.W., Mills, P., Murdoch, A., **Pera, M.F.**, Scott, C.T., Tizzard, J., Warnock, M., Zernicka-Goetz, M., Zhou, Q. & Zoloth, L. Erratum: Revisiting the Warnock rule. Nat Biotechnol 35: 1211 (2017). [Citations:3]
43. Rivron, N., **Pera, M**., Rossant, J., Martinez Arias, A., Zernicka-Goetz, M., Fu, J., van den Brink, S., Bredenoord, A., Dondorp, W., de Wert, G., Hyun, I., Munsie, M. & Isasi, R. Debate ethics of embryo models from stem cells. Nature 564: 183-185 (2018).
44. **Pera, M**. Perspectives from the New Editor-in-Chief, Martin Pera. Stem Cell Reports 12: 1-2 (2019).

Conference Abstracts and presentations from 1997
(Indicates keynote or invited presentation)*

van Schaik, R.H.N.Caricasole, A.A.D., , Zeinstra, L.M., Wierinkx, C.D.J., **Pera, M.F.**,Looijenga, L.H.J., Oosterhuis, J.W., van den Eijinden-van Raiij, A.J.M. and de Jong, F.(1997). Human growth-differentiation factor 3 (hGDF-3): regulation by activin A and retinoic acid in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. (Endocrine Society, Minneapolis, USA).

Henegariu, O., Heiber, D., Honchel, R., Alles, C., Vance, G., **Pera, M.** and Heerema, N.A. (1997). Triple color FISH detection of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes. Proc. Am. Assoc. Cancer Res. 38: 416.

Pera, M.F., Bennett, W. and Cerretti, D.P.(1997). Expression of CD30 and CD30 ligand in cultured cell lines from testicular germ cell tumours. 4th Copenhagen Workshop, Carcinoma in situ and cancer of the testis. Copenhagen.

Trounson, A.O., and **Pera, M.F.** (1997). Potential benefits of cell cloning for human medicine. Genes and Environment in Human Reproductive Disorders, Adelaide.

***Pera, M.F.** (1997) Testicular stem cells and cancer. Hormones and Men's Health, Melbourne.

F.H. de Jong, R.H.N. van Schaik, C.D.J. Wierikx, J.P. de Winter, L.H.J. Looijenga, J.W. Oosterhuis, A. Caricasole, **Pera, M.F.** & A.J.M. van den Eijnden-van Raaij Expression of inhibin subunits, follistatin and activin receptors in normal testicular cells and testicular tumors. In Inhibin, activin and follistatin: recent advances and future views. T. Aono, H. Siguno, and W.W. Vale, eds. pp. 76-84. Springer-Verlag, New York. (1997). [Ctiations: 3]

Caricasole, A.A.D., van Schaik, R.H.N., Zeinstra, L.M., Wierinkx, C.D.J., Looijenga, L.H.J., Oosterhuis, J.W., **Pera, M.F.**, de Jong, F., and van den Eijinden-van Raiij, A.J.M. Analysis of the response of human embryonal carcinoma cells to activin A. In: Inhibin, activin and follistatin: recent advances and future views. T. Aono, H. Siguno, and W.W. Vale, eds. pp. 308-311. Springer-Verlag, New York. (1997). [Citations: 5]

Pera, M.F. and Herzsfeld, D. (1998) Gene expression in human embryonal carcinoma cells: candidate regulators of pluripotent stem cell status. Keystone Conference on Vertebrate Development, Steamboat Springs, Colorado. April 1998.

***Pera, M.F.** (1998). Growth and differentiation of human multipotent stem cells. The Cloning Symposium, Melbourne, April 1998.

Voyle, R., Haines, B., **Pera, M.F**, Forrest, R., Pelton, T. and Rathjen, P. (1998). Novel human leukemia inhibitory factor in mRNAs in human embryonal carcinoma cell lines. National Scientific Conference of the Australian Society for Medical Research.

Voyle, R.B., Haines, B.P., **Pera, M.F.**, Forrest, R., Pelton, T.A. and Rathjen, P.D. (1998). Novel leukemia inhibitory factor transcripts in human EC cell lines encode differentially localised proteins. 17th Annual Conference of the Australian and New Zealand Society for Cell and Developmental Biology.

BE Reubinoff, **Pera, M.F.,** A Bongso, C Fong and A Trounson. Derivation of a human embryonic

stem cell line from a human blastocyst.

American Society for Reproductive Medicine, Toronto, Sept 1999.

*Human pluripotent stem cells: past, present and future. BE Reubinoff, **Pera, M.F.,** D. Herszfeld, A Bongso, C Fong and A Trounson. ART, Science and Fiction. 2nd International Alpha Congress, Sept 1999.

Regulation of human pluripotent stem cell differentiation by bone morphogenetic protein-2. Daniella Herszfeld, Jessica Andrade, and **Pera, M.F.** Combio 99, Brisbane, October 1999.

***Pera, M.F.** Overview on stem cell biology. Australian Society for Biomaterials, 10th Annual Meeting, Biomaterial Opportunities for the Future. Melbourne February 2000.

Regulation of the novel serine proteinase testisin in testicular cancer. KJ Boucaut, DL Nicol, JD Hooper, M Douglas, DR Fitzpatrick, **Pera, M.F.** TM Antalis.. Urological Society of Australian, Sydney, March 2000.

Development and characterization of a xenograft model of human testicular cancer. C Varol, M. Douglas, K Higgins, **Pera, M.F.,** TM Antalis, DL Nicol.

Urological Society of Australian, Sydney, March 2000)

***Pera, M.F.**, BE Reubinoff Jacqui Johnson, Daniella Herszfeld, Souheir Houssami and A Trounson. Human pluripotent stem cells. Serono symposium on Embryos, Embryonic Stem Cells, and Transplantation. Canberra April 2000.

***Pera, M.F.**, BE Reubinoff Jacqui Johnson, Daniella Herszfeld, Souheir Houssami and A Trounson. Human pluripotent stem cells. IMSUT Symposium for Stem Cell Biology, Tokyo June 2000.

***Pera, M.F.,** Johnson, J Reubinoff B Houssami S Herszfeld D Andrade J and Trounson A. Human Pluripotent Stem Cells. Cloning, Stem Cells and Cell Therapy. Edinburgh Sept 2000.

*** Pera, M.F.,** Johnson, J Reubinoff B Houssami S Herszfeld D Andrade J and Trounson A. Human Pluripotent Stem Cells. ICDCB, Gold Coast, Sept 2000.

The role of CD30 in the maintenance of malignant human pluripotent stem cells.

Daniella Herszfeld[1], Emma Langton -Bunker[1], Benjamin E. Reubinoff[1,2], Souheir Houssami[1], Leendert H.J. Looijenga[3], and **Pera, M.F.** ICDCB Gold Coast, Sept 2000.

BMP-2 regulation of the differentiation of human pluripotent stem cells.

Jessica Andrade, Jacqui Johnson, Benjamin E. Reubinoff, Souheir Houssami, Alan Trounson, and **Pera, M.F.** ICDCB Gold Coast, Sept 2000

*Human pluripotent stem cells. Invited lecture, Genomics Institute of the Novartis Research Foundation, La Jolla, Ca November 2000.

*Human pluripotent stem cells. 23rd Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation. Kyoto. December 9. 2000.

***Pera, M.F.** Johnson J Herszfeld D Andrade J Houssami S Reubinoff B Trounson A. Human pluripotent stem cells. Cold Spring Harbor Conference on stem and progenitor cells. March 2001.

***Pera, M.F.** Human cloning and pluripotent stem cell research. Human embryo research manipulation and ethics. Carolyn Chisolm Centre for Health Ethics, Melbourne May 2001.

***Pera, M.F.** Derivation and Differentiation of human embryonic stem cells. Royal Society Discussion Meeting, Stem Cells. London June 2001.

***Pera, M.F.** Multipotent stem cells. New Medicine and the Technology of Stem Cells, University of New South Wales, Sydney June 2001

***Pera, M.F.** Stem cell research. 6th Multidisciplinary Conference on Parkinsons Disease, Melbourne August 2001.

***Pera, M.F.** Johnson J Herszfeld D Andrade J Houssami S Reubinoff B Trounson A. Human Pluripotent Stem Cells. Human embryonic stem cells: prospects for human health. University of Sheffield, UK, September 2001.

***Pera, M.F.** Human embryonic stem cells. American Association for the Study of Liver Diseases. Dallas, November 2001.

***Pera, M.F.** Establishment differentiation and characterization of human embryonic stem cells. Seoul Symposium on stem cells and therapeutic cloning, Seoul November 2001.

***Pera, M.F.** Biology of embryonic stem cells. IFFS Trilogy Speaker, Melbourne November 2001.

***Pera, M.F.** Human pluripotent stem cells. Australian Flow Cytometry Group, Melbourne November 2001.

***Pera, M.F.** Human pluripotent stem cells. MIRD/PHIMR Symposium on Reproductive Genomics, Melbourne December 2001.

***Pera, M.F.** Human embryonic stem cells. March 2002 Taiwan Society of Obstetrics and Gynecology, Tapei.

***Pera, M.F.** Human embryonic stem cells: work in progress. June 2002 NIGMS Symposium on the Basic Biology of Pluripotent Stem Cells. Bethesda Md.

***Pera, M.F.** Australian Society of Nephrology, June 2002

***Pera, M.F.** August 2002 Jackson Laboratory course Current Protocols in Stem Cell Biology Faculty. Maine August 2002

*** Pera, M.F.** MDIBL stem cell conference Stem Cells by Land and Sea. Maine August 2002.

***Pera, M.F.** Embryonic stem cells. Sept 2002 Haematology Society of Aust & NZ, Annual Scientific Meeting – Adelaide SA

A Filipczyk, A. L. Laslett, S. H. Houssami & **Pera, M.F.** Effects of Insulin Function in supporting the growth of Human Embryonic Stem Cells COMBI02002, Sydney NSW, 2002

***Pera, M.F**. Human embryonic stem cells:characterization growth and differentiation. October 2002 33rd Paterson Institute Conference Stem Cells Manchester UK

***Pera, M.F**. Human embryonic stem cells. Kobe Takeda Foundation Symposium: Stem Cells and Organogenesis, Nov 2002

***Pera, M.F** Embryonic stem cells, American Society of Hematology – . Philadelphia 2002.

***Pera, M.F.** Forum on Spinal Cord Injury and Conditions, Sydney NSW, Jan 2003

***Pera, M.F.** The Croucher Foundation Advanced Study Institute (ASI), Hong Kong *Advances and Challenges of Stem Cell Research,* Mar 2003

***Pera, M.F.**, Jessica Andrade, Susan Hawes, Souheir Houssami, Andrew Laslett, Alice Pebay, and Tomonbu Gion Human embryonic stem cells: pluripotent cells and their progeny Mar 2003 Keystone Symposia from Stem Cells to Therapy – Colorado

***Pera M.F.**, Stem Cell Workshop – Pittsburgh, April 2003

***Pera, M.F,** Reality Check - A Summit of Young Adults with diabetes – Melbourne

Stem Cell Research Update, May 03 2003

***Pera, M.F,** St George Hospital – Sydney NSW, May 22 2003

***Pera, M.F,** CSIRO Horizons in Livestock Sciences – Seaworld Nara Resort – Qld

The impact of the new biology *Embryonic stem cells: a future in agricultural biotechnology?*, May 26 2003

***Pera, M.F.,** Australian Society for Medical Research – UK, May 30 2003

***Pera, M.F.,** 2nd Stem Cell Workshop, The Prince of Wales Hospital, Sydney NSW, June 04 2003

Potential Clinical Applications of Stem Cells for Neurological disorders

***Pera, M.F.,** Australian Society of Medical Research Seminar – Sydney NSW, Therapeutic Cloning, June 04 2003

***Pera, M.F.**, Culture techniques for human embryonic stem cells.– NIH Stem Cell Symposium and Workshop Washington DC, June 09 2003

***Pera, M.F.**, Biopharmaceuticals : Concept to Clinic Conference - CSIRO – Melbourne Convention Centre *Cell & Gene Therap,* July 04 2003

***Pera, M.F.**, Diabetes One – JDRF Research Symposium and Expo – Perth, *Latest Developments in Stem Cell Research incl. New techniques to turn mouse and human embryonic stem cells into insulin producing cells,* July 13 2003

***Pera, M.F.**, Towards Renal Regeneration Symposium – University of Queensland, *Pushing Human Embryonic Stem Cells towards Mesoderm,* July 17 2003

***Pera, M.F.**, Current Protocols in Stem Cell Biology – The Jackson Laboratory – Bangor – USA, August 3 to 8 2003

***Pera, M.F.**, Peter MacCallum Clinical Grand Rounds– Peter MacCallum Cancer Institute – East Melbourne

Human Embryonic Stem Cells: Progress & Future Prospects, September 1, 2003

***Pera, M.F.**, Stem Cells: From Genetics to Cell Therapy - Lund Stem Cell Center – Sweden, Sept 5 to 7 2003

***Pera, M.F.,** National Stem Cell Centre Scientific Conference – Melbourne, Human Embryonic Stem Cells: Signalling and Proliferation – *Control of Human Embryonic Stem Cell Maintenance and Commitment,* Oct 9 to 12 2003

***Pera, M.F.,** Australian Gastroenterology Week (AGW) – Cairns, *Human Embryonic Stem Cells: Present Status / Future Prospects* Oct 8, 2003

***Pera, M.F.,** Haematology Society of Australia and New Zealand (HSANZ) Annual Scientific Meeting – Christchurch, New Zealand *Human Embryonic Stem Cells* October 19, 2003

AA Filipczyk AL Laslett S Houssami **Pera, M.F.,** Cell cycle properties of human embryonic stem cells. Keystone Stem Cell Symposium, CO USA. Winner, student scholarship. January 2004

***Pera, M.F,** Instructor and Invited Lecturer, Frontiers in human embryonic stem cells. University of Pitttsburgh, USA, March 2004

***Pera, M.F.** Human embryonic stem cells. Australian Society of Rheumatology, Cairns, April 2005.

***Pera, M.F.** Human embryonic stem cells: characterization, maintenance and differentiation. Insitute for Stem Cell Research Edinburgh UK. June 2004.

***Pera, M.F.** Human embryonic stem cells five years on. Renal Research Consortium Symposium, Brisbane July 21, 2004

***Pera, M.F.** Stem cell research in diabetes. Diabetes; the benefits of prioritisation. International Diabetes Institute Forum, Melbourne July 29, 2004.

***Pera, M.F** . Current protocols in stem cell biology. The Jackson Laboratories, Bar Harbor Maine. Course Director. August 8-13, 2004

***Pera, M.F.** Neural progenitors from human embyronic stem cells. International Congress of Eye Research, Sydney. August 9, 2004.

***Pera, M.F.** Human embryonic stem cells: current status. Australian Institute of Bioengineering and Nanotechnology. August 18, 2004.

***Pera, M.F.** Extrinsic factors regulating the growth and differentiation of human embryonic stem cells. 2004 Seoul Symposium on Stem Cell Research, Seoul, Korea, September 2, 2004.

***Pera, M.F** Laslett A Pebay A Hawes S Wolvetang E Dottori M. Human embryonic stem cells: the first five years. 10th International Congress of the Society of Hematology Asia Pacific Division. Nagoya, Japan September 4, 2004.

***Pera, M.F.** Unnatural selection of human embryonic stem cells. Second Annual Conference of the Australian Stem Cell Centre. Sydney, November 22, 2004.

***Pera, M.F.** Growth and differentiation of human embryonic stem cells. Stem cells: from biology to therapy. 2004 Hanson Symposium Adelaide. November 21, 2004.

***Pera, M.F.** Meeting of the Steering Group of the International Stem Cell Initiative, London, UK, March 11, 2005.

***Pera, M.F,**. Regulation of human embryonic stem cell differentiation. Walter Cottman Symposium, Melbourne, March 24, 2005.

***Pera, M.F.** Growth and differentiation of human embryonic stem cells. Asia-Pacific Meeting on Human Embryonic Stem Cell Research, Kyoto, Japan April 18, 2005.

***Pera, M.F,** Andrew Laslett, Alice Pebay, Susan Hawes, Ernst Wolvetang, and Mirella Dottori. Differentiation hierarchies in human embryonic stem cell cultures defined by immunotranscriptional analysis.Human Genome Meeting, Kyoto, Japan. April 19, 2005.

***Pera M.F,** Stem cells 101 and an update on human embryonic stem cells. Recent Advances in Stem Cell Sciences and Therapies, Annual Meeting of the Australian Academy of Sciences, Canberra May 6, 2005.

***Pera, M.F**. Human embryonic stem cells: the state of the art. Emerging issues in stem cell therapy. Gene and Related Therapies Advisory Panel of the NHMRC Symposium. Canberrra May 10, 2005.

***Pera, M.F**. Human embryonic stem cells: the state of the art. American Transplant Congress, Seattle Washington USA. May 22, 2005.

***Pera, M.F**. Paracrine interactions and the growth and differentiation of human embryonic stem cells. ISSCR Annual Meeting, San Franscisco June 2005.

Adam Filipczyk, Andrew Laslett, **Pera, M.F**. Cell cycle and growth control of human embryonic stem cells. ISSCR Annual Meeting, San Francisco, June 2005.

***Pera, M.F**. Human ES cells: gene expression, genetic stability and endoderm differentiation. University of Minnesota Stem Cell Institute. June 2005.

* **Pera, M.F**. Stem cell research and diabetes-an update. International Diabetes Institute Melbourne. July 2005

***Pera, M.F**. International Society for Experimental Haematology. Glasgow, Scotland. July 30-August 2, 2005
***Pera, M.F**. Human Embryonic stem cells: gene expression and early differentiation. 15th International Society of Developmental Biologists Congress 2005, Sydney Australia. Sept 3-7, 2005

***Pera, M.F**. Maintenance and commitment of human embryonic stem cells. Symposium on cell and tissue engineering, California USA, Sept 18-19 2005

***Pera, M.F**. Development of Conditions for Defined Culture and scale up. California Institute for Regenerative Medicine: Stem cell research: Charting new directions for California, San Francisco, Oct 1-2 2005

***Pera, M.F**. Maintenance and commitment of human embryonic stem cells, St Vincent's Symposium 2005, Sydney Australia, Oct 14, 2005

***Pera, M.F**. Ex vivo differentiation of Embryonal stem cells. Haematology Society of Australia and New Zealand. 2005 Annual Scientific Meeting. Sydney, Australia. October 16-19, 2005

***Pera, M.F** . Maintenance and commitment of human embryonic stem cells

2005 ISAC Samuel A Latt Conference incorporating the ASCC Third Annual Scientific Conference, Gold Coast, November 6-9, 2005
***Pera, M.F**. Control of self renewal and early lineage commitment of human embryonic stem cells International Symposium Germ Cells, Epigenetics, Reprogramming and Stem Cells. Kyoto University, Kyoto, Japan. Nov 15-18 2005

***Pera, M.F.** International Alliances and Stem Cell Landscape (Panel member). International Symposium on Stem Cell Collaboration. Mission Bay Conference Centre at UCSF, San Francisco, California February 7, 2006

***Pera, M.F.** Transnational Cooperation in Stem Cell Research (Steering Committee) Hinxton, Cambridge, UK. February 22-24, 2006

***Pera, M.F.** Human embryonic stem cells: past present and future. Institute of Molecular Biosciences, University of Queensland, Brisbane, Australia. March 2006.

***Pera, M.F.** The cell biological basis of embryonic stem cell technology. Cell culture engineering X. April 2006, Whistler, Canada.

***Pera, M.F.** Understanding, Maintaining and Using Human Embryonic Stem Cells. R+D Systems, Minneapolis, Minnesota, 14 September 2006.

***Pera, M.F.** Renewal and Commitment of Human Embryonic Stem Cells. International Society for Differentiation, Innsbruck, October 7-11, 2006.

***Pera, M.F.** Characterization Maintenance and Differentiation of Human Embryonic Stem Cells. International Symposium on Stem Cells and Regenerative Medicine, Tapei, Taiwan October 21-22 2006

***Pera, M.F.** Human Embryonic Stem Cells. First Latin American Conference on Regenerative Medicine, Buenos Aires, Argentina, October 27-28 2006.

***Pera, M.F.** Understanding Maintaining and Using Human Embryonic Stem Cells. UCLA, Los Angeles, 2 November 2006.

***Pera, M.F.** Control of Renewal and Commitment of Human Embryonic Stem Cells. The Biology of Stem Cells, 16th Beckman Symposium, Duarte California November 3 2006.

***Pera, M.F.** Understanding Maintaining and Using Human Embryonic Stem Cells. Dean's Lecture Series, University of Washington, Seattle, 15 November 2006.

***Pera, M.F.** Human Embryonic Stem Cells-The State of the Art. DeWatteville Lecture, FIGO World Congress, Kuala Lumpur 8-9 November 2006.

***Pera, M.F.** Neural Differentiation of Human Embryonic Stem Cells. 4th Congress of the Federation of Asian-Oceanian Neuroscience Societies. Hong Kong November 30-December 2, 2006.

***Pera, M.F.** Prospects for the Application of embryonic Stem Cells in Developmental Toxicology. Health and Environmental Sciences Institute. South Carolina, February 27-28, 2007.

***Pera, M.F.** Stem Cell Research and Therapies/Apoptosis in Drug Discovery. La Jolla, San Diego, California. March 22-23, 2007

***Pera, M.F.** Embryonic Stem Cells in Drug Discovery. American Association of Pharmaceutical Scientists. National Biotechnology Conference, San Diego, California. June 23-28, 2007.

***Pera, M.F.** NF-κB signaling in Human Embryonic Stem Cells. International Society for Stem Cell Research (ISSCR). Cairns, Queensland, Australia. June 17-20, 2007.

***Pera, M.F.** Develop quality control and scale-up methods consistent with future translational studies. NIH Blueprint Stem Cell Workshop, Bethesda. June 28-29, 2007.

***Pera, M.F.** Understanding and maintaining Human Embryonic Stem Cells. Stem Cell Manchester-The Northwest Initiative. Manchester, UK. July 16-18, 2007.

***Pera, M.F.** Human Embryonic Stem cells- State of the Art. American Association of Pharmaceutical Scientists' student chapter's scientific symposium, Moving Targets. August 24, 2007.

***Pera, M.F.** Understanding, Maintaining and Using Human Embryonic Stem Cells. Lund Stem Cell Center Meeting. Sweden, September 10-12, 2007

***Pera, M.F.** Understanding, Maintaining and Using Human Embryonic Stem Cells. International Symposium on Regenerative Medical Therapy, September 19-20, 2007

***Pera, M.F.** Understanding, Maintaining and Using Human Embryonic Stem Cells. Mackay International Conference, Taiwan. November 17-18, 2007

***Pera, M.F.** Stem Cells 101, American Academy of Pediatrics Conference, San Francisco, October 29, 2007

***Pera, M.F.** Human Embryonic Stem Cells; from Pluripotency to Neuroregeneration, Winter Conference on Brain Research, Snowbird, Utah, January 26-February 1, 2008

***Pera, M.F.** Invited guest, Berkeley Stem Cell Conference, San Francisco, February 6, 2008

***Pera, M.F.** Characterization, genetic stability and differentiation of human ES cells. Millipore Asia Bioforum; Advances in Epigenetics and Stem cell research. March 5, 2008

***Pera, M.F.** Hepatic progenitor cells for a pre-clinical model of liver disease. RCLD Annual symposium, March 21, 2008

***Pera, M.F.** Understanding, maintaining and using human embryonic stem cells. Monash University, Australia. April 16, 2008

***Pera, M.F.** 15th Annual Meeting of the American Society for Neural Therapy and Repair. Clearwater Beach, FL Date: May, 2008

***Pera, M.F.** The Science of Hope: Stem Cell research. USC Leonard Davis School of Gerontology; Leadership retreat, LA, California, April 25-27

***Pera, M.F.** Understanding and Maintaining Human Embryonic Stem Cells. ILS-Biomed and 2nd International Stem Cell Meeting; The potency of Stem Cells. Tel Aviv, Israel, May 27-29, 2008.

***Pera, M.F.** ES Tools; Advances with Human Embryonic Stem cells. Second Annual Consortium Meeting in Budapest 1-5 June 2008

***Pera, M.F.** Endocrine Society 90th Annual Meeting; Primal Endocrinology; the TGF beta super-family in early mammalian development. San Francisco, June 17, 2008

***Pera, M.F.** The Teratology Society, 48th Annual meeting. Human embryonic stem cells and the control of growth and differentiation of human pluripotent stem cells. Monterey, July 1, 2008

***Pera, M.F.** Understanding and Maintaining Human Embryonic Stem Cells. The 13th Annual Mayo-Lutheran Forum on Hematopoietic and stem cells; The Emerging Embryonic Stem Cell Therapies. July 18, 2008.

***Pera, M.F.** Understanding and Using Human Embryonic Stem Cells. City of Hope Stem Cell Seminar Series. Duarte, USA, September 5, 2008

***Pera, M.F.** Altered States of Pluripotency, The 10th Annual International Stem Cell Initiative. Bar Harbor Maine, October 13, 2008

***Pera, M.F.**. ES Cell Derivation and Differentiation, Methods in Human Embryonic Stem Cell Research. Bar Harbor Maine, October 16, 2008

***Pera, M.F.**. Update on Stem Cell Research, Medical Education Speakers Network , Glendale, November 24, 2008

Pera, M.F. California Scientist: CIRM-MRC Workshop. San Francisco, California, January 12-13, 2009

Pera, M.F. Expert Panel: Tutorial Presenter. Beckman Initiative for Macular Research: Vision for the Future through Interdisciplinary Discovery, Irvine, California January 22-23, 2009

Pera, M.F. ES Tools Winterschool; Maintenance of pluripotency. Finland, January 26-30, 2009

***Pera, M.F**. Invited Guest Speaker, Seminar: Stem Cell Research Center-Institute for Frontier Medical Sciences, Japan, February 14-20, 2009

***Pera, M.F**. Protein Markers of Stem CellsThe Human Embryonic Stem Cell Microenvironment, a Challenge to Proteomics. Wellcome Trust, Perspectives in Stem Cell Proteomics Conference, UK, March 22-23, 2009

***Pera, M.F**. Pluripotent Stem Cells in Neurology. Neurorehabilitation/ Medicine Grand Rounds, Rancho Los Amigos National Rehabilitation Center- Downey California, April 2009

***Pera, M.F.** The Many States of Pluripotency. University of Kansas Medical Center A.L.Chapman Lecture April 2009.

***Pera, M.F.** The Many States of Pluripotency. ESHRE 25th Annual Meeting, Amsterdam, June 2009.

***Pera, M.F.** The Many States of Pluripotency. Queenstown Molecular Biology Meeting, New Zealand, August 2009

***Pera, M.F.** The Many States of Pluripotency. University of Melbourne Stem Cell Interest Group Symposium, September 2009

***Pera, M.F.** The Many States of Pluripotency. Second Annual Stem Cell Symposium Cornell University, September 2009

***Pera, M.F**. The Many States of Pluripotency. Institute for Molecular Medicine, University of Texas-Houston, January 2010

***Pera, M.F**. Human Embryonic Stem Cells: The State of the Art. Scientific Program and Dinner-LA Obstetrical and Gynecological Society, February 2010

***Pera, M.F**. The Many States of Pluripotency. California Institute Regenerative Medicine, 2nd Annual Grantee Meeting, March 2010

***Pera, M.F.** The Many States of Pluripotency, Sabah Research Institute, Los Angeles, CA, April 2010

***Pera, M.F.** Human ES Cell Culture : A Practical Approach, Animal Models for Stem Cell Therapy Workshop, The Jackson Laboratory, Maine, USA, 1st – 4th May, 2010

***Pera, M.F.** The Many States of Pluripotency, Minnesota Stem Cell Institute, 21st October, 2010

***Pera, M.F.** A novel marker for endodermal progenitor cells in tissue repair and transformation, The International Society Differentiation, Japan, November 2010

***Pera, M.F.** The Many States of Pluripotency, Frontiers in Biomedical Research Hong Kong University, Hong Kong, December 2010

***Pera, M.F.** Stem Cells and the Future of Medicine, Innovation Fund Skolkovo Centre Meeting, Moscow, January 2011

***Pera M.F.** Human Pluripotent Stem Cells : The State of the Art. FDA Committee of Veterinary Medicine Rockville, MD, USA, February 2011

***Pera, M.F.** Human Pluripotent Stem Cells: The State of the Art, 4th International Friederich's Ataxia Scientific Conference, Strasbourg, France, May 2011

Pera, M.F. A novel marker for endodermal progenitor cells in tissue repair and transformation, ISSCR 9th Annual Meeting, Canada, June 2011

***Pera, M.F.** The Metastable State of Pluripotency, Stem Cell and Regenerative Medicine Mini Symposium, National Science Council, 20 – 23 July 2011, Taiwan
Pera, M.F. Safety Issues in Stem Cell Therapies: Immunogenecity, Tumorgenicity and Genetic Stability (moderator) 2011 World Stem Cell Summit, Pasadena, CA, 3rd – 5th October, 2011

***Pera, M.F.** The Metastable State of Pluripotency, Department of Biochemistry, University of Georgia, 7th October, 2011

***Pera, M.F.** Human Pluripotent Stem Cells – back to the future, Rediscovering Pluripotency: From Teratocarcinomas to Embryonic Stem Cells, Cardiff, UK, 10th – 12th October, 2011

***Pera, M.F.** Human Pluripotent Stem Cells, The Australasian Society for Stem Cell Research, 4th Annual Meeting, 23rd - 25th October, 2011, NSW, Australia

***Pera, M.F**. Embryonic Stem Cells and Induced Pluripotency, International Society for Cellular Therapy, Sydney, Australia, 2nd November,2011,

***Pera, M.F**. Dana Forbes Cancer Institute, Boston, 18th November, 2011

***Pera, M.F.** A Close Look at Human Pluripotent Stem Cells, Indo-Australia Biotechnology Conference on "Stem Cell Biology" December, 2011, Bangalore, India

Pera, M.F. Stem Cells Australia Inaugural Retreat, April, 2012

Pera, M.F. Panel Member for the External Review of the University of Minnesota Stem Cell Institute, Minneapolis April, 2012.

Pera, M.F. Stem Cell Bank, Pokrovsky, Russia, April, 2012

Pera, M.F. ISSCR, 10th Annual Meeting, Yokohama, Japan, June, 2012

***Pera, M.F.** 1st International Conference on BioNano Innovation (ICBNI), QLD, Australia, July, 2012

Pera, M.F. 9th Australia-China Symposium on Healthy Ageing; New approaches from genomics, stem cells and smart technologies, Canberra, Australia, 2012

Pera, M.F. ComBio2012 (Co- Chair) Symposium on Stem Cells & Regeneration; Adelaide, Australia September 2012

***Pera, M.F**. UNIST 2nd International Symposium on Reprogramming and Stem Cells; Busan, South Korea, October 2012

***Pera, M.F**. Annual Meeting, Australian and New Zealand Spinal Cord Society, Melbourne, Australia, October 2012

***Pera, M.F**. Ausbiotech 2012 National Conference, Panel Chair, Melbourne, Australia

***Pera, M.F** European Commission**,** DG Research & Innovation - Consensus meeting in Brussels , November 2012

Pera, M.F. Stem Cells Australia Annual Retreat, Victoria, Australia, November 2012

***Pera, M.F**. Hunter Cellular Biology Annual Meeting, NSW, Australia, March 2013

***Pera, M.F.** WEHI Student Meeting, Healesville, Australia, April 2013

***Pera, M.F.** Australian Veterinary Association National Conference, Cairns, Australia, May 2013

***Pera, M.F.** ISSCR June, 2013

***Pera, M.F.** ISCI, Bar Harbour, June, 2013

***Pera, M.F.** GPCME, New Zealand, June , 2013

***Pera, M.F**. Bootes Course for Translational Medicine, ANU College of Medicine, Canberra, Australia July, 2013

***Pera, M.F.** Centre for Stem Cell Research, The University of Adelaide, Australia, July 2013

***Pera M.F.** International Congress of Pediatrics, Melbourne, Australia, August, 2013,

***Pera, M.F.** Centre for Eye Research Australia, Annual Retreat, Victoria, Australia, October, 2013

***Pera, M.F.** Stem Cells Australia Annual Retreat, Queensland, Australia, November 2013,

***Pera, M.F.** CIRM Review, San Francisco, USA, November 2013

***Pera, M.F.** NSW Stem Cell Network Workshop, Australia, November 2013

***Pera, M.F.** 13th Congress Japanese Society for Regenerative Medicine – Kyoto, Japan. 2nd March – 7th March 2014

***Pera, M.F.** International Expert Advisory Panel - Canadian Stem Cell Strategy, Toronto, Canada. 9th March – 11th March 2014

***Pera, M.F.** Cell Reprogramming Australia Inc. 2nd Annual Collaborative Conference –5th and 6th June 2014

***Pera, M.F.** Victorian Institute of Forensic Medicine. 11th June 2014

***Pera, M.F.** ISSCR 2014 Annual Meeting, Vancouver, Canada Invited panellist – Focus Session. 18th June – 21st June

***Pera, M.F.** Human Frontier Sciences Project 14th HFSP Awardees Meeting, Lugano, Switzerland. 4th July

***Pera, M.F.** Taiwan Review Review the proposals of Stem Cell Research Program funded by Ministry of Science and Technology of Taiwan, R. O. C. 20th July

***Pera, M.F.** International Conference on Systems Biology 2014 – Melbourne. 8 September 2014

***Pera, M.F.** Palo Alto NHLBI Progenitor Cell Biology Consortium (PCBC) Cell Characterization Futures Workshop, California.September 28, 2014

***Pera, M.F.** Epilepsy Genetics in the Era of Precision Medicine, California. September 29-30, 2014

***Pera, M.F.** Nature Conference--Nuclear Reprogramming Guangzhou. October 31-November 2, 2014

***Pera, M.F.** Cell Therapy and Regenerative Medicine. Fifth Margaret River Region Conference.N Busselton, Western Australia. November 3-5, 2014

***Pera, M.F**. Young Investigators Symposium, Stem Cell Society of Singapore, Singapore, June 2015

Pera, M.F. International Society of Stem Cell Research Stockholm, Sweden 24-27 June 2015

***Pera, M.F.** Human Science Frontiers Program Grantees Meeting, La Jolla CA , 2015 (abstract)

Pera, M.F. Chair. Theo Murphy Think Tank The Stem Cell Revolution: Lessons for Australia. Australian Academy of Sciences, Sydney 2015

Pera, M.F. New South Wales Stem Cell Network Sydney 6 April 2016. Stem Cells Back to the Future.

***Pera, M.F.** IPITA IXA CTS Joint Conference Melbourne November 2015. Stem cells and regenerative medicine: the future is now.

***Pera, M.F.** International Tissue Transplantation Society Hong Kong The promise of stem cells: nullius in verba

***Pera, M.F.** Taiwan International Stem Cell Conference Taipei 16-17 October Human Pluripotent Stem Cells and the Mammalian Embryo

***Pera, M.F.** Ausbiotech Melbourne October 25 2016. Stem cells and regenerative medicine: the future is now.

Pera, M.F. Hong Kong Conference on Stem Cells and Regenerative Medicine

***Pera, M.F.** UK Inaugural Regenerative Medicine Meeting London 19 December. Human pluripotent stem cells: biology matters.

Pera, M.F. Hong Kong and Guangzhou International Conference on Stem Cells and Regenerative Medicine Hong Kong December 2016. Regulation of cell therapy and stem cell research.

***Pera, M.F.** The Vernon Plueckhahn Oration, Barwon Health, Geelong 14 February 2017. The Genome Editing and Stem Cell Revolutions: Over the Horizon.

***Pera, M.F**. Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cells.

ISSCR Regional Conference on Translational Opportunities in Stem Cell Research, Basel, 27 February 2017.

***Pera, M.F.** Human pluripotent stem cells and human embryogenesis. Maine Biological and Medical Sciences Symposium. 28-29 April 2017.

***Pera, M.F.** Human pluripotent stem cells and the embryo. Ivan Damjanov Lecture, University of Kansas 1 June 2017.

***Pera, M.F**. Human pluripotent stem cells and the embryo. Physical Concepts in Stem Cell Biology, Tisvildeleje, Denmark Aust 6-8 2017.

***Pera, M.F.** Genetic and epigenetic stability of human pluripotent stem cells. 4th Cell Therapy

Conference: Manufacturing and Testing of Pluripotent Stem Cells.

The International Alliance for Biological Standardization, Los Angeles CA 5-6 June 2018.

***Pera, M.F.** Biological Biological Effects of Recurrent Genetic Variants in Human Pluripotent Stem Cells. Nature Round Table: Challenges in Ensuring hPSC Quality. London, 17 September 2018.

***Pera, M.F.** Human Pluripotent Stem Cells and the Human Embryo. Academia Sinica, Taiwan, October 2018.

***Pera, M.F.** Human Pluripotent Stem Cells and the Human Embryo. 14th Annual Meeting of the Taiwan Society for Stem Cell Research. October 26-27 2018

Pera, M.* Human pluripotent stem cells and the human embryo. Keynote speaker, 3rd Annual University of Buffalo Stem Cells in Regenerative Medicine Symposium

Pera, M.* HESI CT-TRACS Meeting Tumorigienicity International Multi-Site Study Focus Day 27 Washington DC September 2019 Genomic Instability.

Pera, M.* UKRMP / BPS Joint Meeting Safety for Stem Cell Edinburgh October 2019. Recurrent Genetic Variants in Human Pluripotent Stem Cell Culture and Their Biological Significance

Pera, M.* Invited Speaker, Stanford Cardiovascular Institute Frontiers Seminar Series, JAN 2020 Human pluripotent stem cells from a developmental perspective.

Pera, M. Co-Chair and Invited Speaker. National Academy of Sciences Workshop on Examing the State of the Science of Mammalian Embryo Model Systems, Washington D.C., 17 January 2020.

Pera, M. SMA Foundation Axon and Muscle Health Workshop, New Orleans, LA, 23-24 January 2020.

Pera, M. Invited Speaker, Human Pluripotent Stem Cells, the Human Embryo, and the Self-Renewing State, Stanford Cardiovascular Institute, Palo Alto, 4 February 2020.

Pera, M. MAGIC Consortium Human Pluripotent Stem Cells and Germ Cell Tumors, 29 April 2020.

Pera, M. Session Chair and Invited Speaker, Unique Properties of a Subset of Human Pluripotent Stem Cells with a High Capacity for Self-Renewal, ISSCR 2020 Virtual Meeting, 23-27 June 2020.

Pera, M. "Human Pluripotent Stem Cells and the Human Embryo," UTSW Seminar Series. 1 September 2020

Pera, M. Organizer and Invited Speaker. Undefined Defined Medium: ISCI/ISCBI Dicussion Topic. ISCI/ISCBI Satellite Workshop (Canadian Stem Cell Network, Till and McCulloch Meeting), 25 October 2020.

Pera, M. Organizer and Invited Speaker. Biological Consequences of Recurrent Genetic Variants in Human Pluripotent Stem Cells. ISCI/ISCBI Satellite Workshop (Canadian Stem Cell Network, Till and McCulloch Meeting), 25 October 2020.

Pera, M. "Human pluripotencdy past present and future." Thorsten Boroviak Lab, University of Cambridge, 5 November 2020.

Pera, M. Human Pluropotent Stem Cells and the Human Embryo, ASHBI Bioethics and Biology Fusion Seminar Series, Kyoto University, 3 February 2021.

Pera, M. Human Pluripotent Stem Cells and the Human Embryo, Tufts University, Department of Genetics, 17 February 2021.

Pera, M. Human Pluripotent Stem Cells and the Human Embryo, Institute Genetics and Biophysics, CNR Seminar Program, Naples, Italy, 19 April 2021.

Pera, M. International Symposium and Workshops on Development of hPSC for Clinical Application, PS Conference 2021, Bridging Session: engaging Chinese Networks and International Groups, Beijing, China, 26 May 2021.